Professor Des Richardson

Professor & NHMRC Senior Principal Research Fellow
Pathology, School of Medical Sciences
Bosch Institute

Telephone +61 2 9036 6548
Fax +61 2 9351 3429

Map

Research interests

Professor Richardson’s major contributions to cancer research are focussed on understanding the role of iron in cancer cell proliferation and the development of novel anti-tumour agents known as iron chelators. Indeed, these studies have resulted in highly promising and potent anti-cancer drugs and are subject of a suite of active national patents.

Current research students

Project title Research student
The Metastasis Suppressor, NDRG1, as a Novel Molecular Target for the Treatment of Aggressive Breast Cancer Faten (SHEHADEH TOUT)
Glutathione-S-Transferase Machinery and its Role as a Novel Nitric Oxide Storage and Transport System in Macrophage Biology Taufik ABIDIN
Molecular Functions of NDRG1 as Metastasis Suppressor in Prostate Cancer Syer Choon LIM
Pharmacological Targeting of Oncogenic and Tumour Suppressive Pathways, and their Interaction with the Tumour Microenvironment in Pancreatic Cancer using the Metastasis Suppressor, NDRG1 Bekesho Geleta WENDIMU
Investigating the effect of novel thiosemicarbazones on FGFR and VEGFR expression and activity in breast cancer sub-types Madiha YUNUS

Selected grants

2019

  • Pharmacological and Pharmaceutical Development of Novel Drugs for Multiple Major Disease States; Richardson D; National Health and Medical Research Council (NHMRC)/Research Fellowships.

2018

  • Targeting the metastasis suppressor NDRG1 for the treatment of advanced heterogeneous breast cancer; Richardson D, Kovacevic Z, Kalinowski D, Clarke C; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Development of Innovative Chemotherapeutics that Target P-Glycoprotein-Expressing Cancers to Overcome Drug Resistance; Jansson P, Richardson D; Cancer Institute NSW/Career Development Fellowship.
  • To Biochemically Tricking P-Glycoprotein (Pgp) to Target Resistance via Lysosomal Pgp; Richardson D, Bernhardt P, Jansson P, Kalinowski D; National Health and Medical Research Council (NHMRC)/Project Grants.
  • NSW Molecular analysis Platform: FTICR Mass Spectrometry and CHN&S analyser; Groundwater P, Payne R, Gale P, Karuso P, Kumar N, McCluskey A, Mitchell T, Doble P, Richardson D, Codd R, Rodger A, Venkatesan K, Raftery M, Donald W, Williams D; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).
  • HoloMonitor M4 Live Cell Analysis System for Shared Use in the Open Access, Multi-User, Bosch Molecular Biology Facility; Richardson D, Long G, Scolyer R; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Melanotransferrin: A �Missing Link� and a Novel Pharmacological Target for Treatment; Richardson D, Lane D, Kovacevic Z, Suryo Rahmanto Y, Wilmott J, Weeraratna A; National Health and Medical Research Council (NHMRC)/Project Grants.
  • IPDF-ST Fac Exchange Prog-D Richardson; Richardson D; Office of Global Engagement/IPDF Grant.

2017

  • Hormone Transport by Alpha-2-Macroglobulin: Novel Roles in Regulating Hormone Activity; Richardson D, Subramaniam N, Trinder D, Huang M, Clark R, Ganz T; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Development of Novel Agents that Target P-Glycoprotein Resistant Pancreatic Cancer; Richardson D, Jansson P, Kalinowski D, Sahni S; Avner Pancreatic Cancer Foundation/Research support.
  • Commercial Translation of Innovative Null Hepcidin Analogs that Prevent the Anaemia of Chronic Disease; Richardson D, Meyer-Carrive I, Huang M; National Foundation for Medical Research and Innovation (NFMRI)/Social Investment Portfolio 2.
  • Development of Innovative Multi-Functional Drugs for the Treatment of the Multiple Pathologies in Alzheimer's Disease; Richardson D; Rebecca L Cooper Medical Research Foundation/Research Grant.
  • Nrf2 and Friedreich's Ataxia; Richardson D; DVC Research/Bridging Support Grant.

2016

  • Targeting Mitochondrial Homeostasis in the Pathogenesis of Friedreich's Ataxia; Huang M, Richardson D; Muscular Dystrophy Association (USA)/Research Support.
  • Fast Linear Laser Scanning Technology: The ZEISS LSM 800 Confocal Microscope for the Open Access, Bosch Institute Advanced Microscopy Facility; Richardson D, Scolyer R, Braet F, Chan-Ling T, Mason R, Halliday G, Byrne S, Bourne R, Lyons G, Charles (nee Slaviero) K; Cancer Institute NSW/Equipment Grant.
  • A New Achilles Heel in Prostate Cancer: Novel Regulators of Polyamine Homeostasis.; Richardson D, Lane D, Anderson G, Subramaniam V; Prostate Cancer Foundation of Australia/Concept Grants.
  • Identification of the Specific Structure-Activity Relationships of Thiosemicarbazones To Overcome Multidrug Resistance by Exploiting Lysosomal Drug Pumps in Breast Cancer; Richardson D, Jansson P, Lee S, Bernhardt P, Bao B, Kovarikova P, Wand H; National Breast Cancer Foundation/Pilot Study Grants.
  • A Multi-Target Approach to Alzheimer's Disease: Novel Polyfunctional Therapeutics that Target Multiple Hallmarks; Richardson D, Kalinowski D, Bush A; Equity Trustees Limited/Mason Foundation National Medical Research.
  • Hormone Transport by Alpha-2-Macroglobulin; Richardson D; DVC Research/Bridging Support Grant.
  • Advanced NanoSight NS300 System; Halliday G, Richardson D, Chan H, Grau G, Shackel N; University of Sydney/Equipment Grant.

2015

  • Advanced Technical Support for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility; Richardson D; Cancer Institute NSW/Research Infrastructure Grant.
  • Biacore T200 Molecular Interaction Analysis System for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Long G, Halliday G, Murray M, Lee C, Kumar N, Mason R, Payne R, Lay P; Cancer Institute NSW/Equipment Grant.
  • Portable Infrared Spectroscopy Equipment for Cancer Diagnosis, Research into Prevention of Cancer by Understanding the Role of Diet, and for Drug Development and Studies on Efficacy; Lay P, Richardson D, Banati R, Biro M, Bebawy M, Graeber M, Grau G, Hambley T, New E, Carter E; Cancer Institute NSW/Equipment Grant.
  • Cancer invasion and metastasis: how actin networks control cell movement in 3 dimensional environments; O'Neill G, Biro M, Dehghani F, Chrzanowski W, Richardson D; DVC Research/SPARC Implementation - Cancer.
  • Hypoxic Chambers for Seahorse XF Extracellular Flux Analyzers; Richardson D, Scolyer R, Ng M, Murray M, Kril J; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Automated High Throughput Hypoxic Live Cell Imaging System; Halliday G, Richardson D, Long G, Mason R, Murphy C; DVC Research/Equipment Grant.

2014

  • Senior Principal Research Fellowship - Biomedical Investigations of Pharmacology and Pathology for Disease Treatment; Richardson D; National Health and Medical Research Council (NHMRC)/Career Awards: Research Fellowships.
  • The Physiological Role of Glutathione-S-Transferase in the Intracellular Storage and Transport of Nitric Oxide and its Biomedical Effects; Richardson D, Hawkins C; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Pharmacological Targeting of Integrated Oncogenic and Tumour Suppressive Pathways using Novel Therapeutics; Richardson D, Kovacevic Z, Kalinowski D; National Health and Medical Research Council (NHMRC)/Project Grants.
  • CLARIOstar Multifunctional Microplate Reader for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Huang M, Scolyer R, Fraser S, Sahni S, Speranza T, Owens T, Barrs V, Ju Y, Kovacevic Z, Lu Z, Camp A, Slobedman B, Morris B, Oliver B, Dos Remedios C, Kalinowski D, Fu D, Lai D, Lovicu F, Allbutt H, Triccas J, Burgess J, Kril J, Dixon K, Rendina L, Byrne M, King N, Groundwater P, Williamson P, Ho P, Dong Q, Bao B, Assinder S, McLennan S, Richardson D, Ammit A, Sharland A, Hardikar A, Hong A, Hambly B, Lee C, Murphy C, Goldsbury C, Johnstone D, Lane D, Hibbs D, Joshua D, Huq F, Halliday G, Sutherland G, Zreiqat H, Lok H, Lyons G, Jansson P, Black J, Zhu L, Sunde M, Day M, Naylor M, Buckland M, Murray M, Shafie N, Lay P, Poronnik P, Codd R, Mason R, Ryan R, Christopherson R, de Graaf S; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • La Vision BioTec Ultramicroscope; Murphy C, Braet F, Byrne M, Chan-Ling T, Fraser S, Goldsbury C, Halliday G, Hambly B, Johnstone D, Keay K, Lovelace M, Lyons G, Mason R, Overall R, Owens T, Richardson D, Stone J, Weiss A; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • Novel Aminoguanidine Schiff Base Chelators as Potential Anti-Cancer Agents; Domb A, Richardson D; DVC Research/International Research Collaboration Award (IRCA).
  • BioMark HD High-throughput Real Time & Digital PCR System for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Lee C, Halliday G, Murray M, Lay P, Christie M, Kench J, Damian D, Hersey P; Cancer Institute NSW/Equipment Grant.
  • CyTOF Mass Cytometry Platform; Fazekas de St Groth B, Weninger W, Richardson D, Halliday G, Gunning P, Hart D, Mann G, Goldys E, Jin D; Cancer Institute NSW/Equipment Grant.
  • A high-throughput, bright-field and fluorescence digital slide scanning platform and service that is both research and teaching-focused and available University-wide.; King N, Graeber M, Naylor M, Slapeta J, Quinnell R, Charles (nee Slaviero) K, Owens T, Bourne R, Braet F, Hambly B, Overall R, Stone J, Twigg S, Hardikar A, Halliday G, Richardson D, Byrne M, Keay K, Marsh D, Howell V, Pollock C, Chen X; DVC Research/Equipment Grant.
  • Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho P, Williamson P, Murphy C; DVC Research/Equipment Grant.
  • QX100 Droplet Digital PCR system for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Richardson D, Kril J, Murphy C, Vandenberg R, Rendina L, Dos Remedios C, Ju Y, Kovacevic Z, Lyons G, Sutherland G, Lay P, Ammit A, Lai D, Morris B, Day M, Dong Q, Bao B, Huang M, Camp A, Boyer M, Whittington R, Byrne M, Hanrahan J, Fu D, Jansson P, Lane D, Bagley E, Hibbs D, Zhang D, Fraser S, Scolyer R, Black J, Halliday G, Christie M, Zreiqat H, Murray M, Slobedman B, Naylor M, Burgess J, Triccas J, Mason R, Chadban S, Combes V, Lovicu F, McLennan S, Kalinowski D, Sharland A, Johnstone D, Groundwater P, Dixon K, Zhou F, Lovejoy D, Lu Z, Zhu L, Goldsbury C, Witting P, Buckland M, Assinder S, Purdie (Williams) A, Codd R, Owens T, Hambly B; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2012

  • Advanced Technical Support for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility.; Richardson D; Cancer Institute NSW/Research Infrastructure Grant.
  • A new treatment strategy for pancreatic cancer; Richardson D, Kovacevic Z; National Health and Medical Research Council (NHMRC)/Early Career Fellowships.
  • Investigating the Cellular Response to Iron-Depletion: The Trilogy of ASK1, Thioredoxin and Ribonucleotide Reductase; Richardson D, Hawkins C, Suryo Rahmanto Y, Lovejoy D, Ponka P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • IncuCyte FLR Imaging System for Cancer Researchers at the Multi-User Bosch Molecular Biology Core Facility; Richardson D; DVC Research/Cancer Research Fund.
  • Bruker Daltonics autoflex speed MALDI-TOF/TOF mass spectrometer; Baxter R, Halliday G, Marsh D, Gill A, Clarke S, Smith R, Little C, Jackson C, O'Neill C, Murphy C, Sharland A, Chadban S, Mason R, Assinder S, Verdurand M, Richardson D, Machaalani R, Hambly B, Chan-Ling T, Dos Remedios C, Holsinger D, Lay P; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Pre-clinical Development of a Novel Second Generation Chemotherapeutic for Cancer Therapy; Richardson D, Lovejoy D, Mills J; National Health and Medical Research Council (NHMRC)/Development Grants.
  • Pharmacology of potential anti-tumour agents: Iron and copper chelators of the ApT, BpT and DpT classes; Richardson D, Lovejoy D, Brunk U; National Health and Medical Research Council (NHMRC)/Project Grants.
  • GeneAtlas Personal Microarray System; Richardson D, Scolyer R, Stocker R, Weninger W, Black J, Allen D, Murray M, Mason R, Twigg S, King N, Horvath L, Lovicu F, Lee C, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufogalis B, Hambly B, Morris B, Bao B, Bishop A, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina L, Byrne M, Naylor M, Cole N, Jansson P, Dong Q, Codd R, Payne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto A, Lai D, Yu Y, Ju Y, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes R, Zhang D, Boyer M, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Upgrade of the Palm Duoflex Combi Laser Microdissection and Optical Tweezers System to a High-resolution and Improved Live-cell Imaging Platform using an Apotome.2 Slider and Associated Software; Cole L, Mason R, Richardson D, Phillips W, Bao B, Buckland M, Morris M, Dos Remedios C; Rebecca L Cooper Medical Research Foundation/Equipment Grant.

2011

  • Development of iron complexes for the treatment of Friedreichs Ataxia; Richardson D, Ponka P; Muscular Dystrophy Association (USA)/Research Support.
  • Seahorse Extracellular Flux (XF) Analyzer for the Multi-Disciplinary Sydney Cancer Research Core Facility; Richardson D; Cancer Institute NSW/Equipment Grant.
  • xCELLigence Real Time Cell Monitoring System for Bosch ProstatCancer Research Focus Group in the Multi-User Bosch Institute Molecular Biology Facility; Richardson D; Prostate Cancer Foundation of Australia/Equipment Grants.
  • Development of Novel Anti-Tumour Agents: chelator-nanoparticles; Richardson D; Office of Global Engagement/IPDF Grant.
  • The small animal bioimager; Halliday G, Hambley T, Zreiqat H, Richardson D, Holst J, Rasko J, Byrne S, Dong Q, Hong A, Lyons G; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Identifying the mechanisms by which ascorbate stimulates cellular iron uptake from transferrin.; Lane D, Richardson D; National Health and Medical Research Council (NHMRC)/Early Career Fellowships.
  • The Effect of Anthracyclines on the Iron Metabolism of Leukaemia Cells.; Richardson D, Kalinowski D; Cancer Institute NSW/Research Innovation Grants.
  • Development of Iron Complexes for the Treatment of Friedreichs Ataxia & the Role of Frataxin in Iron Metabolism; Richardson D, Suryo Rahmanto Y, Ponka P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • PyroMark Q96 ID system; Richardson D, Stone J, Black J, King N, Mason R, Hunt N, Kril J, Murray M, Scolyer R, Halliday G, Vandenberg R, McMinn P, Chadban S, Byrne M, Ryan R, Dong Q, Lee C, Bishop A, Haass N, Fraser S, Hambly B, Sharland A, Kalinowski D, Assinder S, Yu Y, Bao B, Ju Y, Lovejoy D, Buckland M, Lane D, Dos Remedios C, Kovacevic Z, Sutherland G, Zhang D, Morris B, Suryo Rahmanto A, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2010

  • GenomeLab GeXP Genetic Analysis System for the Multi-Disciplinary Sydney Cancer Gene Expression Facility; Richardson D, Halliday G, Scolyer R, Clarke S, Lee C, Reichardt J, Clarke C, Murray M, Boyer M, Kefford R; Cancer Institute NSW/Equipment Grant.
  • High speed 3D live cell imaging of cancer genesis, growth, metastasis and death.; Weninger W, Vadas M, Richardson D, Fazekas de St Groth B, Gamble J, McCaughan G, Rasko J, Shackel N, Haass N; Cancer Institute NSW/Equipment Grant.
  • Integration of ecogenic and tumour suppresive pathways in prostate cancer and investigation of their potential roles in treatment; Richardson D, Assinder S; DVC Research/Cancer Research Fund.
  • Pharmacological Targeting via AKT, PTEN, and TGF-beta Pathway Integration using Novel Therapeutics; Richardson D, Assinder S, Dong Q; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Luminex 200 Analysis System for the Bosch Prostate Cancer Research Focus Group in the Multi-User Institute Molecular Biology Facility; Richardson D; Prostate Cancer Foundation of Australia/Equipment Grants.
  • Determination of the Mechanisms of Pathogenesis of Friedreichs Ataxia and the Use of Novel Iron-Containing Molecules to Rescue the Metabolic Defect due to Frataxin Deficiency; Richardson D, Becker E; Friedreichs Ataxia Research Alliance (USA)/FA Translational Research.
  • The Effect of Nitrogen Monoxide on Intracellular Iron Metabolism; Richardson D; Australian Research Council (ARC)/Discovery Projects (DP).
  • Alpha-2-macroglobulin and the transport and uptake of the hormone, hepcidin; Richardson D, Suryo Rahmanto Y, Kuchel P; National Health and Medical Research Council (NHMRC)/Project Grants.

2009

  • PALM Microbeam Laser Microdissection (LM) Microscope for the Multi-User Sydney Cancer Gene Expression Facility; Richardson D; Cancer Institute NSW/Infrastructure Grant.
  • Development of Novel Drugs for the Treatment of Breast Cancer; Jansson P, Richardson D, Lovejoy D, Kalinowski D; Australian Rotary Health/Research Support.
  • autoMACS Pro Separator; Abendroth A, Britton W, Richardson D, King N, Halliday G, Pollard J, McMinn P, Bishop A, Triccas J, Wang M, Byrne S; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Inverted Multiphoton Intravital Microscope; Weninger W, Gorrell M, Halliday G, Jones C, Fazekas de St Groth B, Richardson D, Clarke S, Gamble J, Bertolino P, Vadas M, Dong Q, Rasko J, Holst J, McCaughan G, Byrne S, Saunders B, Triccas J, Haass N; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • NHMRC Senior Prinipal Research Fellow; Richardson D; National Health and Medical Research Council (NHMRC)/Career Awards: Research Fellowships.
  • Development of novel and selective chemotherapeutics for treatment of pancreatic cancer; Richardson D; Cancer Council New South Wales/Innovator Grant.
  • StreamLineTM Plus- Rapid Chemical Mapping; Lay P, Grau G, Richardson D, Hambley T, Witting P, Carter E; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class; Richardson D, Kalinowski D, Lovejoy D, Bernhardt P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Core Resource Facility - application for 7-laser flow cytometer and high content bioimaging system to enhance capabilities and throughput for the NSW Advanced Cytometry Facility; King N, Vadas M, Campbell I, Grau G, Britton W, Fazekas de St Groth B, Richardson D, Halliday G, Christopherson R, Gamble J, Mason R, Rasko J, McCaughan G, Weninger W, Xia P, Gorrell M, Holst J, Pile A, Sword G, McArthur C, Dong Q, Haass N, Sharland A, Saunders B, Triccas J, Norris J, Bertolino P, Bowen D, Sze D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Development of Novel Anti-Cancer Drugs with Marked and Selective Activity that Overcome Resistance to established Chemotherapy; Kalinowski D, Richardson D; Cancer Institute NSW/Early Career Fellowship.
  • 7-laser BD LSR-II and Cellomics Array Scan VTi to Enhance Capability and Throughput for the NSW Advanced Cytometry Facility; King N, Weninger W, Gunning P, Fazekas de St Groth B, Campbell I, Christopherson R, Black J, Mason R, Richardson D, Halliday G, Grau G, Gandevia S, Kachigian L, Geczy C, Jessup W, Vadas M, Britton W, Hunt N; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).
  • Multi-photon microscope for intravital imaging; Weninger W, Vadas M, Hogg P, Norris M, Fazekas de St Groth B, Haass N, Clarke S, Halliday G, Rasko J, Holst J, McCaughan G, Allen J, Gamble J, Dong Q, Byrne S, Richardson D; Cancer Institute NSW/Equipment Grant.
  • The Role of Melanoma Tumour Antigen p97 (Melanotransferrin) in Melanoma Tumourenesis; Richardson D, Suryo Rahmanto Y; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The Combined Efficacy of Anti-Oxidants and Iron Chelation as a Potential Treatment for Friedreichs Ataxia: Studies Using MCK/Frda Conditional Knockout Mouse; Richardson D, Becker E; Muscular Dystrophy Association of New South Wales/Research Support.
  • Toxicological and pre-clinical assessment of the anti-cancer compound Bp4eT; Richardson D, Lovejoy D, Mills J; National Health and Medical Research Council (NHMRC)/Career Development Awards.
  • Molecular Examination of the Role of Iron in Oestrogen-Dependant and -independant Growth of Breast Cancer Cells; Kalinowski D, Lovejoy D, Richardson D; Cancer Institute NSW/Research Innovation Grants.
  • LightCycler 480 Real-Time PCR System; Richardson D; Prostate Cancer Foundation of Australia/Equipment Grants.
  • A new Laser Microdissection Microscope with a unique pressure catapulting technique allows isolation of pure samples for subsequent downstream molecular analyses; Halliday G, Morris B, Mason R, Murphy C, Bishop A, Leamey C, Joshua D, Lee C, Iland H, Pamphlett R, Richardson D, King N, Hunt N, Arnold J, Morris M, Protti D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • A Multi-Resolution X-ray Microtomography Facility (NanoCT & MicroCT) for Non-Destructive 3D Characterisation; Munroe P, Jones A, Zhou H, Cairney J, Einav I, Swain M, Murphy C, Seibel M, Ringer S, Li Q, Darendeliler M, Wang X, Zhang Y, Hand S, Archer M, Ramzan I, Young P, Traini D, Richardson D, Masters A, Milthorpe B; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).

2008

  • Development of Novel Anti-Tumour Agents for the Treatment of Malignant Melanoma; Richardson D; Melanoma and Skin Cancer Research Institute/Research Support.
  • Establishment of a Breeding Colony of the NSE "Neurological Conditional Knockout Model and the use of Mitochondrial Permeable Iron Chelators as a Potential treatment for Friedreich's Ataxia"; Richardson D; Friedreichs Ataxia Research Alliance (USA)/Research Support.
  • Development of Novel Anti-tumour Drugs for the Treatment of Prostate Cancer: Targeting the Drug-Induced Expression of the Tumour Metastasis Suppressor Drg-1; Richardson D; Prostate Cancer Foundation of Australia/Project Grants.
  • Development of Iron Chelators for the Treatment of Friedreichs Ataxia and the Role of Frataxin in Mitochondrial Iron Metabolism; Richardson D, Davies M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The role of iron in Friedreich's Ataxia and the Use of Ireon Chelation Therapy; Richardson D; Muscular Dystrophy Association (USA)/Research Support.
  • a/ Barnstead Nanopure Diamond water system life science UV/UF b/ 1800mm Class II Biological Safety Cabinet x2 c/ Innova 44, Innova 44R, Incubator shakers d/ Emulsiflex-C5r Homogeniser (Ceramic) e/ Western Blotting Apparatus package; Richardson D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Pre-Clinical Development of Second Generation DpT Iron Chelators for the Treatment of Melanoma; Richardson D, Jansson P; Cure Cancer Australia Foundation/Research Support.
  • Lipocalin 2 in host defence of the central nervous system; Campbell I, King N, Richardson D; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Understanding the Pathogenesis of Friedreich's Ataxia to Aid in the Development of New Therapeutic Regimes; Richardson D; Friedreichs Ataxia Research Alliance (USA)/Research Support.

2007

  • PHERSAstar and POLARstar optima multifunctional plate readers with robotic high throughout screening system for multi-disciplinary cancer research; Grau G, Hunt N, Richardson D; Cancer Institute NSW/Research Grant.
  • Rotor-Gene 6000, 5-Plex HRM with desktop computer & Gene-Disc 100 Stater Kit; Halliday G, Yue D, Sharland A, Bishop A, Stocker R, Bao B, McLennan S, Matsumoto I, Hambly B, Rose B, Harbour C, Ho P, Lee C, Twigg S, Soon L, Richardson D, King N, Zreiqat H; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Development of novel drugs for the inhibition of prostate cancer metastasis: Relationship to drug-induced expression of the tumour metastasis suppressor, Drg-1; Jormakka M, Rapp M, Richardson D, Curmi P, Von Heijne G; Australian Research Council (ARC)/Linkage International: ARC International Fellowships (ARCIF).
  • Development of novel drugs for the inhibition of prostate cancer metastasis: Relationship to drug-induced expression of the tumour metastasis suppressor, Drg-1; Richardson D; Australian Rotary Health/Research Grant.
  • NHMRC - Research Fellowship; Richardson D; National Health and Medical Research Council (NHMRC)/Established Career Fellowships.
  • The effect of nitrogen monoxide on intracellular iron metabolism; Richardson D; Australian Research Council (ARC)/Discovery Projects (DP).
  • PHERAstar and POLARstar Optima multi-functional plate readers with robotic high throughput screening system for multi-disciplinary cancer research; Halliday G, Ho P, Conigrave A, Iland H, Lee C, Joshua D, Cook D, Richardson D, Reichardt J, Grau G, Lovejoy D, Hunt N, King N, Mason R, Murphy C, Sharland A, Assinder S, Dong Q, Bishop A; Cancer Institute NSW/Infrastructure Grant.
  • Pre-clinical development of DpT iron chelators for cancer treatment; Richardson D, Lovejoy D, Boyer M, Horvath L; Cancer Institute NSW/Research Grant.
  • Examination of the Molecular Pharmacology of Anthracyclines Induced via their Interaction with Iron; Richardson D, Lovejoy D, Bernhardt P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Development of novel and selective anti-tumour agents for the treatment of brain cancer; Richardson D, Lovejoy D; Australian Rotary Health/Research Grant.
  • Chemical and Biochemical Characterisation of Novel Iron Chelators with Therapeutic Potential; Bernhardt P, Richardson D; Australian Research Council (ARC)/Discovery Projects (DP).

2006

  • Mitochondrial iron overload and friedrichs ataxia: The role of frataxin in iron metabolism; Becker E, Richardson D; Friedreichs Ataxia Research Alliance (USA)/Research Grants Program.
  • Chemical and biochemical characterisation of novel iron chelators with therapeutic potential; Richardson D; Australian Research Council (ARC)/Discovery Projects (DP).
  • The role of iron in Friedreichs ataxia and the use of iron chelation therapy; Richardson D; Muscular Dystrophy Association (USA)/Project Support.
  • The effect of nitrogen monoxide on intracellular iron metabolism; Richardson D; Australian Research Council (ARC)/Discovery Projects (DP).
  • Novel complexes of gallium as potent anti-leukaemia and lymphoma agents; Richardson D, Lock R; The Leukaemia Foundation of Australia Limited/Grants in Aid.
  • Prf; National Health and Medical Research Council (NHMRC)/Established Career Fellowships.
  • Effect of Iron chelators with potent anti-tumour activity on the expression of the tumour metastasis suppressor, Drg-1 in Brest cancer; Richardson D, Lovejoy D; Australian Rotary Health/Mental Health Research Grants.
  • Potential anti-tumour agents: iron chelators of the pyridoxal isonicotinoyl hydrazone class; Richardson D; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Role of the oncogenes, c-myc and N-myc, in the regulation of molecular mechanisms involved in iron metabolism and cancer cell proliferation; Richardson D; University of Sydney/Research & Development.
  • Mitochondrial Iron Overload and Friedreichs Ataxia: The Role of Frataxin in Iron and Haem Metabolism; Richardson D, Davies M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Iron Chelation Efficacy Of Novel Pcih Iron Chelators In Vivo And Their Ability To Prevent The Pathology Observed In The Conditional Frataxin Knockout Mouse; Richardson D; Friedreich Ataxia Research association Australasia/Grant-in-Aid.
  • Melanotransferrin; Richardson D; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Books

  • Suryo Rahmanto, Y., Richardson, D. (2008). The Physiological and Pathophysiological Roles of Melanotransferrin: Role of Melanotransferrin in Cell Proliferation, Migration and Melanoma Tumourigenesis. Saarbrucken, Germany: VDM Verlag Dr Muller.

Book Chapters

  • Richardson, D. (2009). Chelators as Anti-Cancer Drugs. In Manfred Schwab (Eds.), Encyclopedia of Cancer, Vol. 1, (pp. 598-601). Germany: Springer.
  • Kalinowski, D., Richardson, D. (2008). Cellular and Molecular Biology of Iron-Binding Proteins. In Rudolfs K. Zalups, D. James Koropatnick (Eds.), Cellular and Molecular Biology of Metals.
  • Lovejoy, D., Yu, Y., Richardson, D. (2008). Chelators as Anti-Cancer Drugs. In Manfred Schwab (Eds.), Encyclopedia of Cancer, Vol. 1. Germany: Springer.
  • Suryo Rahmanto, Y., Sekyere, E., Dunn, L., Richardson, D. (2008). The function of the membrane-bound transferrin homolog, melanotransferrin (melanoma tumour antigen p97). In H. Fuchs (Eds.), Iron Metabolism and Disease, (pp. 219-239). Kerala, India: Research Signpost.

Journals

  • Lane, D., Bae, D., Siafakas, A., Rahmanto, Y., Al-Akra, L., Jansson, P., Casero Jr., R., Richardson, D. (2018). Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1864 (9 Part B), 2793-2813. [More Information]
  • Park, K., Menezes, S., Kalinowski, D., Sahni, S., Jansson, P., Kovacevic, Z., Richardson, D. (2018). Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1864 (8), 2644-2663. [More Information]
  • Richardson, D. (2018). Laying Down a Solid �Iron Foundation�: Professor Erica Baker. Biochimica et Biophysica Acta - General Subjects, 1862 (10), e1-e2. [More Information]
  • Chiang, S., Kalinowski, D., Jansson, P., Richardson, D., Huang, M. (2018). Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia. Neurochemistry International, 117, 35-48. [More Information]
  • Palanimuthu, D., Wu, Z., Jansson, P., Braidy, N., Bernhardt, P., Richardson, D., Kalinowski, D. (2018). Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease. Dalton Transactions, 47(21), 7190-7205. [More Information]
  • Bae, D., Lane, D., Jansson, P., Richardson, D. (2018). The old and new biochemistry of polyamines. Biochimica et Biophysica Acta - General Subjects, 1862 (9), 2053-2068. [More Information]
  • Saleh Moussa, R., Kovacevic, Z., Bae, D., Lane, D., Richardson, D. (2018). Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21(CIP1/WAF1), by the chelator, Dp44mT. Biochimica et Biophysica Acta - General Subjects, 1862 (3), 761-774. [More Information]
  • Al-Akra, L., Bae, D., Sahni, S., Huang, M., Park, K., Lane, D., Jansson, P., Richardson, D. (2018). Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones. Journal of Biological Chemistry, 293(10), 3562-3587. [More Information]
  • Palanimuthu, D., Poon, R., Sahni, S., Anjum, R., Hibbs, D., Lin, H., Bernhardt, P., Kalinowski, D., Richardson, D. (2017). A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 139, 612-632. [More Information]
  • Menezes, S., Sahni, S., Kovacevic, Z., Richardson, D. (2017). Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling. Journal of Biological Chemistry, 292(31), 12772-12782. [More Information]
  • Fouani, L., Menezes, S., Paulson, M., Richardson, D., Kovacevic, Z. (2017). Metals and metastasis: Exploiting the role of metals in cancer metastasis to develop novel anti-metastatic agents. Pharmacological Research, 115, 275-287. [More Information]
  • Anzovino, A., Chiang, S., Brown, B., Hawkins, C., Richardson, D., Huang, M. (2017). Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3(beta) Axis. American Journal of Pathology, 187(12), 2858-2875. [More Information]
  • Shi, L., Ito, F., Wang, Y., Okazaki, Y., Tanaka, H., Mizuno, M., Hori, M., Hirayama, T., Nagasawa, H., Richardson, D., Toyokuni, S. (2017). Non-thermal plasma induces a stress response in mesothelioma cells resulting in increased endocytosis, lysosome biogenesis and autophagy. Free Radical Biology and Medicine, 108, 904-917. [More Information]
  • Xi, R., Pun, I., Menezes, S., Fouani, L., Kalinowski, D., Huang, M., Zhang, X., Richardson, D., Kovacevic, Z. (2017). Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1). Molecular Pharmacology, 91(5), 499-517. [More Information]
  • Kovacevic, Z., Sahni, S., Lok, H., Davies, M., Wink, D., Richardson, D. (2017). Regulation and control of nitric oxide (NO) in macrophages: Protecting the "professional killer cell" from its own cytotoxic arsenal via MRP1 and GSTP1. Biochimica et Biophysica Acta - General Subjects, 1861 (5), 995-999. [More Information]
  • Yanatori, I., Richardson, D., Toyokuni, S., Kishi, F. (2017). The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer. Journal of Biological Chemistry, 292(32), 13205-13229. [More Information]
  • Sahni, S., Bae, D., Jansson, P., Richardson, D. (2017). The mechanistic role of chemically diverse metal ions in the induction of autophagy. Pharmacological Research, 119, 118-127. [More Information]
  • Seebacher, N., Richardson, D., Jansson, P. (2016). A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death and Disease, 7(12), 1-13. [More Information]
  • Lok, H., Sahni, S., Jansson, P., Kovacevic, Z., Hawkins, C., Richardson, D. (2016). A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity. Journal of Biological Chemistry, 291(53), 27042-27061. [More Information]
  • Shi, L., Wang, Y., Ito, F., Okazaki, Y., Tanaka, H., Mizuno, M., Hori, M., Richardson, D., Toyokuni, S. (2016). Biphasic effects of l-ascorbate on the tumoricidal activity of non-thermal plasma against malignant mesothelioma cells. Archives of Biochemistry and Biophysics, 605, 109-116. [More Information]
  • Lane, D., Jansson, P., Richardson, D. (2016). Bonnie and Clyde: Vitamin C and iron are partners in crime in iron deficiency anaemia and its potential role in the elderly. Aging, 8(5), 1150-1152. [More Information]
  • Park, K., Fouani, L., Jansson, P., Wooi, D., Sahni, S., Lane, D., Palanimuthu, D., Lok, H., Kovacevic, Z., Huang, M., Kalinowski, D., Richardson, D. (2016). Copper and conquer: Copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics. Metallomics, 8(9), 874-886. [More Information]
  • Kovacevic, Z., Sahni, S., Richardson, D. (2016). Copper that cancer with lysosomal love!. Aging, 8(2), 210-211. [More Information]
  • Chiang, S., Kovacevic, Z., Sahni, S., Lane, D., Merlot, A., Kalinowski, D., Huang, M., Richardson, D. (2016). Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia. Clinical Science, 130(11), 853-870. [More Information]
  • Seebacher, N., Lane, D., Jansson, P., Richardson, D. (2016). Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter. Journal of Biological Chemistry, 291(8), 3796-3820. [More Information]
  • Klionsky, D., Abdelmohsen, K., Akihisa, A., Abedin, M., Abeliovich, H., Acevedo-Arozena, A., Arozena, H., Adams, C., Adams, P., et al, Sue, C., Mihailidou, A., Bae, D., Gutierrez, E., Jansson, P., Lane, D., Merlot, A., Richardson, D., Sahni, S. (2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 12(1), 1-222. [More Information]
  • Yanatori, I., Richardson, D., Imada, K., Kishi, F. (2016). Iron export through the transporter ferroportin 1 is modulated by the iron chaperone PCBP2. Journal of Biological Chemistry, 291(33), 17303-17318. [More Information]
  • Basha, M., Bordini, J., Richardson, D., Martinez, M., Bernhardt, P. (2016). Kinetico-mechanistic studies on methemoglobin generation by biologically active thiosemicarbazone iron(III) complexes. Journal of Inorganic Biochemistry, 162, 326-333. [More Information]
  • Merlot, A., Sahni, S., Lane, D., Richardson, V., Huang, M., Kalinowski, D., Richardson, D. (2016). Letter to the Editor: Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques"". International Journal of Molecular Sciences, 17(11), E1916. [More Information]
  • Yingchoncharoen, P., Kalinowski, D., Richardson, D. (2016). Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacological Reviews, 68(3), 701-787. [More Information]
  • Gutierrez, E., Seebacher, N., Arzuman, L., Kovacevic, Z., Lane, D., Richardson, V., Merlot, A., Lok, H., Kalinowski, D., Sahni, S., Jansson, P., Richardson, D. (2016). Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT). Biochimica et Biophysica Acta, 1863 (7 Pt A), 1665-1681. [More Information]
  • Merlot, A., Shafie, N., Yu, Y., Richardson, V., Jansson, P., Sahni, S., Lane, D., Kovacevic, Z., Kalinowski, D., Richardson, D. (2016). Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2[alpha], IRE1[alpha], ATF6 and calmodulin kinase. Biochemical Pharmacology, 109, 27-47. [More Information]
  • Al-Eisawi, Z., Stefani, C., Jansson, P., Arvind, A., Sharpe, P., Basha, M., Iskander, G., Kumar, N., Kovacevic, Z., Lane, D., Sahni, S., Richardson, D., Kalinowski, D., et al (2016). Novel Mechanism of Cytotoxicity for the Selective Selenosemicarbazone, 2-Acetylpyridine 4,4-Dimethyl-3- selenosemicarbazone (Ap44mSe): Lysosomal Membrane Permeabilization. Journal of Medicinal Chemistry, 59(1), 294-312. [More Information]
  • Cahill, M., Jazayeri, J., Kovacevic, Z., Richardson, D. (2016). PGRMC1 regulation by phosphorylation: Potential new insights in controlling biological activity!. Oncotarget, 7(32), 50822-50827. [More Information]
  • Paluncic, J., Kovacevic, Z., Jansson, P., Kalinowski, D., Merlot, A., Huang, M., Lok, H., Sahni, S., Lane, D., Richardson, D. (2016). Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. Biochimica et Biophysica Acta, 1863 (4), 770-784. [More Information]
  • Stacy, A., Palanimuthu, D., Bernhardt, P., Kalinowski, D., Jansson, P., Richardson, D. (2016). Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance. Journal of Medicinal Chemistry, 59(18), 8601-8620. [More Information]
  • Sahni, S., Kovacevic, Z., Kalinowski, D., Huang, M., Menezes, S., Krishan, S., Lane, D., Jansson, P., Richardson, D. (2016). Targeting autophagy in antitumor agent design: Furthering the 'lysosomal love' strategy. Future Medicinal Chemistry, 8(7), 727-729. [More Information]
  • Wangpu, X., Lu, J., Xi, R., Yue, F., Sahni, S., Park, K., Menezes, S., Huang, M., Zheng, M., Kovacevic, Z., Richardson, D. (2016). Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling. Molecular Pharmacology, 89(5), 521-540. [More Information]
  • Krishan, S., Richardson, D., Sahni, S. (2016). The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells. Biochimica et Biophysica Acta, 1863 (12), 2916-2933. [More Information]
  • Cahill, M., Jazayeri, J., Catalano, S., Toyokuni, S., Kovacevic, Z., Richardson, D. (2016). The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochimica et Biophysica Acta, 1866 (2), 339-349. [More Information]
  • Kovacevic, Z., Menezes, S., Sahni, S., Kalinowski, D., Bae, D., Lane, D., Richardson, D. (2016). The metastasis suppressor, N-MYC downstream-regulated gene-1 (NDRG1), down-regulates the ErbB family of receptors to inhibit downstream oncogenic signaling pathways. Journal of Biological Chemistry, 291(3), 1029-1052. [More Information]
  • Guo, Z., Richardson, D., Kalinowski, D., Kovacevic, Z., Tan-Un, K., Chan, G. (2016). The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. Journal of Hematology and Oncology, 9(1), 1-16. [More Information]
  • Seebacher, N., Lane, D., Richardson, D., Jansson, P. (2016). Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance. Free Radical Biology and Medicine, 96, 432-445. [More Information]
  • Stacy, A., Palanimuthu, D., Bernhardt, P., Kalinowski, D., Jansson, P., Richardson, D. (2016). Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity. Journal of Medicinal Chemistry, 59(10), 4965-4984. [More Information]
  • Krishan, S., Richardson, D., Sahni, S. (2015). Adenosine Monophosphate-Activated Kinase and Its Key Role in Catabolism: Structure, Regulation, Biological Activity and Pharmacological Activation. Molecular Pharmacology, 87(3), 363-377. [More Information]
  • Bucur, O., Almasan, A., Zubarev, R., Friedman, M., Nicolson, G., Sumazin, P., Leabu, M., Nikolajczyk, B., Avram, D., Kunej, T., Richardson, D., Grau, G., et al (2015). An updated h-index measures both the primary and total scientific output of a researcher. Discoveries, 3(3), 1-6. [More Information]
  • Lane, D., Merlot, A., Huang, M., Bae, D., Jansson, P., Sahni, S., Kalinowski, D., Richardson, D. (2015). Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease. Biochimica et Biophysica Acta - General Subjects, 1853 (5), 1130-1144. [More Information]
  • Jansson, P., Yamagishi, T., Arvind, A., Seebacher, N., Gutierrez, E., Stacy, A., Maleki, S., Sharp, D., Sahni, S., Richardson, D. (2015). Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-Glycoprotein (Pgp). Journal of Biological Chemistry, 290(15), 9588-9603. [More Information]
  • Saleh Moussa, R., Kovacevic, Z., Richardson, D. (2015). Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types. Oncotarget, 6(30), 29694-29711. [More Information]
  • Seebacher, N., Richardson, D., Jansson, P. (2015). Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics. British Journal of Pharmacology, 172(10), 2557-2772. [More Information]
  • Stefani, C., Al-Eisawi, Z., Jansson, P., Kalinowski, D., Richardson, D. (2015). Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization. Journal of Inorganic Biochemistry, 152, 20-37. [More Information]
  • Potuckova, E., Roh, J., Machacek, M., Sahni, S., Stariat, J., Sestak, V., Jansova, H., Haskova, P., Jirkovska, A., Kalinowski, D., Richardson, D., et al (2015). In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PloS One, 10(10), 1-20. [More Information]
  • Krishan, S., Jansson, P., Gutierrez, E., Lane, D., Richardson, D., Sahni, S. (2015). Iron metabolism and autophagy: A poorly explored relationship that has important consequences for health and disease. Nagoya Journal of Medical Science, 77, 1-6.
  • Merlot, A., Kalinowski, D., Kovacevic, Z., Jansson, P., Lane, D., Sahni, S., Huang, M., Richardson, D. (2015). Making a case for albumin - a highly promising drug-delivery system. Future Medicinal Chemistry, 7(5), 553-556. [More Information]
  • Sestak, V., Stariat, J., Cermanova, J., Potuckova, E., Chladek, J., Roh, J., Bures, J., Jansova, H., Prusa, P., Sterba, M., Kalinowski, D., Richardson, D., et al (2015). Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 6(40), 42411-42428. [More Information]
  • Lui, G., Kovacevic, Z., Menezes, S., Kalinowski, D., Merlot, A., Sahni, S., Richardson, D. (2015). Novel Thiosemicarbazones Regulate the Signal Transducer and Activator of Transcription 3 (STAT3) Pathway: Inhibition of Constitutive and Interleukin 6-Induced Activation by Iron Depletion. Molecular Pharmacology, 87(3), 543-560. [More Information]
  • Merlot, A., Sahni, S., Lane, D., Fordham, A., Pantarat, N., Hibbs, D., Richardson, V., Doddareddy, M., Ong, J., Huang, M., Richardson, D., Kalinowski, D. (2015). Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells. Oncotarget, 6(12), 10374-10398. [More Information]
  • Jirkovska, A., Roh, J., Len�?ová-Popelová, O., Jirkovsky, E., Hrušková, K., Potuckova, E., Jansova, H., Haskova, P., Martinková, P., Eisner, T., Kalinowski, D., Richardson, D., et al (2015). Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicology Research, 4(4), 1098-1114. [More Information]
  • Lui, G., Kovacevic, Z., Richardson, V., Merlot, A., Kalinowski, D., Richardson, D. (2015). Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget, 6(22), 18748-18779. [More Information]
  • Wangpu, X., Yang, X., Zhao, J., Lu, J., Guan, S., Lu, J., Kovacevic, Z., Liu, W., Mi, L., Jin, R., Richardson, D., et al (2015). The metastasis suppressor, NDRG1, inhibits "stemness" of colorectal cancer via down-regulation of nuclear B-catenin and CD44. Oncotarget, 6(32), 33893-33911. [More Information]
  • Liu, W., Kovacevic, Z., Peng, Z., Jin, R., Wang, P., Yue, F., Zheng, M., Huang, M., Jansson, P., Richardson, V., Kalinowski, D., Lane, D., Merlot, A., Sahni, S., Richardson, D. (2015). The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: New therapeutic targets. Oncotarget, 6(34), 35522-35541. [More Information]
  • Liu, W., Yue, F., Zheng, M., Merlot, A., Bae, D., Huang, M., Lane, D., Jansson, P., Lui, G., Richardson, V., Sahni, S., Kalinowski, D., Kovacevic, Z., Richardson, D. (2015). The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget, 6(11), 8851-8874. [More Information]
  • Jansson, P., Kalinowski, D., Lane, D., Kovacevic, Z., Seebacher, N., Fouani, L., Sahni, S., Merlot, A., Richardson, D. (2015). The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacological Research, 100, 255-260. [More Information]
  • Sahni, S., Krishan, S., Palanimuthu, D., Richardson, D. (2015). The use of iron chelators in biocidal compositions: evaluation of patent, WO2014059417A1. Expert Opinion on Therapeutic Patents, 25(3), 367-372. [More Information]
  • Krishan, S., Richardson, D., Sahni, S. (2014). AMP kinase (PRKAA1). Journal of Clinical Pathology, 67(9), 758-763. [More Information]
  • Lane, D., Richardson, D. (2014). Can we target the alpha2-macroglobulin-hepcidin interaction to treat pathologic hypoferremia? Future Medicinal Chemistry, 6(1), 13-16. [More Information]
  • Lane, D., Richardson, D. (2014). Chaperone turns gatekeeper: PCBP2 and DMT1 form an iron-transport pipeline. The Biochemical Journal, 462(1), e1-e3. [More Information]
  • Filak, L., Kalinowski, D., Bauer, T., Richardson, D., Arion, V. (2014). Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids. Inorganic Chemistry, 53(13), 6934-6943. [More Information]
  • Lane, D., Mills, T., Shafie, N., Merlot, A., Saleh Moussa, R., Kalinowski, D., Kovacevic, Z., Richardson, D. (2014). Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition. Biochimica et Biophysica Acta-Reviews on Cancer, 1845 (2), 166-181. [More Information]
  • Serda, M., Kalinowski, D., Rasko, N., Potuckova, E., Mrozek-Wilczkiewicz, A., Musiol, R., Małecki, J., Sajewicz, M., Ratuszna, A., Muchowicz, A., Richardson, D., et al (2014). Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships. PloS One, 9(10), 1-15. [More Information]
  • Anzovino, A., Lane, D., Huang, M., Richardson, D. (2014). Fixing frataxin: "ironing out" the metabolic defect in friedreich's ataxia. British Journal of Pharmacology, 171(8), 2174-2190. [More Information]
  • Sahni, S., Merlot, A., Krishnan, S., Jansson, P., Richardson, D. (2014). Gene of the month: BECN1. Journal of Clinical Pathology, 67(8), 656-660. [More Information]
  • Ataie-Kachoie, P., Pourgholami, M., Richardson, D., Morris, D. (2014). Gene of the month: Interleukin 6 (IL-6). Journal of Clinical Pathology, 67(11), 932-937. [More Information]
  • Lok, H., Sahni, S., Richardson, V., Kalinowski, D., Kovacevic, Z., Lane, D., Richardson, D. (2014). Glutathione S-Transferase and MRP1 Form an Integrated System Involved in the Storage and Transport of Dinitrosyl-Dithiolato Iron Complexes in Cells. Free Radical Biology and Medicine, 75, 14-29. [More Information]
  • Basha, M., Rodríguez, C., Richardson, D., Martínez, M., Bernhardt, P. (2014). Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia. Journal of Biological Inorganic Chemistry, 19(3), 349-357. [More Information]
  • Fang, B., Kovacevic, Z., Park, K., Kalinowski, D., Jansson, P., Lane, D., Sahni, S., Richardson, D. (2014). Molecular Functions of the Iron-Regulated Metastasis Suppressor, NDRG1, and its Potential as a Molecular Target for Cancer Therapy. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1845 (1), 1-19. [More Information]
  • Sahni, S., Krishan, S., Richardson, D. (2014). NDRG1 as a molecular target to inhibit the epithelial-mesenchymal transition: the case for developing inhibitors of metastasis. Future Medicinal Chemistry, 6(11), 1241-1244. [More Information]
  • Ellis, S., Kalinowski, D., Leotta, L., Huang, M., Jelfs, P., Sintchenko, V., Richardson, D., Triccas, J. (2014). Potent Anti-Mycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analogue, 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide. Molecular Pharmacology, 85(2), 269-278. [More Information]
  • Potuckova, E., Jansova, H., Machacek, M., Vavrova, A., Haskova, P., Tichotova, L., Richardson, V., Kalinowski, D., Richardson, D., Simunek, T. (2014). Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs. PloS One, 9(2), 1-15. [More Information]
  • Merlot, A., Richardson, D. (2014). Receptor Recognition and Lysosomal Targeting to Enhance Cytotoxicity of Novel Anti-Cancer Agents that Bind Iron and Copper. Vitamins & Trace Elements, 3(1), e125. [More Information]
  • Stariat, J., Suprunova, V., Roh, J., Sestak, V., Eisner, T., Filipsky, T., Mladenka, P., Nobilis, M., Simunek, T., Klimes, J., Kalinowski, D., Richardson, D., et al (2014). Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats. Biomedical Chromatography, 28(5), 621-629. [More Information]
  • Potuckova, E., Hrušková, K., Bures, J., Kovarikova, P., Spirkova, I., Pravdıkova, K., Kolbabova, L., Hergeselova, T., Haskova, P., Jansova, H., Richardson, V., Lane, D., Kalinowski, D., Richardson, D., et al (2014). Structure-Activity Relationships of Novel Salicylaldehyde Isonicotinoyl Hydrazone (SIH) Analogs: Iron Chelation, Anti-Oxidant and Cytotoxic Properties. PloS One, 9(11), 1-17. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2014). Synthesis and biological evaluation of 2-benzoylpyridine thiosemicarbazones in a dimeric system: Structure-activity relationship studies on their anti-proliferative and iron chelation efficacy. Journal of Inorganic Biochemistry, 141, 43-54. [More Information]
  • Lane, D., Richardson, D. (2014). The Active Role of Vitamin C in Mammalian Iron Metabolism: Much More Than Just Enhanced Iron Absorption!. Free Radical Biology and Medicine, 75, 69-83. [More Information]
  • Gutierrez, E., Richardson, D., Jansson, P. (2014). The Anti-Cancer Agent, Dp44mT, Overcomes Pro-Survival Autophagy by Two Mechanisms: Persistent Induction of Autophagosome Synthesis and Impairment of Lysosomal Integrity. Journal of Biological Chemistry, 289(48), 33568-33589. [More Information]
  • Lane, D., Merlot, A., Richardson, D. (2014). The lure of a LYR: The logistics of iron sulfur cluster delivery. Cell Metabolism, 19(3), 348-350. [More Information]
  • Sahni, S., Bae, D., Lane, D., Kovacevic, Z., Kalinowski, D., Jansson, P., Richardson, D. (2014). The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. Journal of Biological Chemistry, 289(14), 9692-9709. [More Information]
  • Merlot, A., Kalinowski, D., Richardson, D. (2014). Unraveling the mysteries of serum albumin-more than just a serum protein. Frontiers in Physiology, 5, 1-7. [More Information]
  • Stefani, C., Jansson, P., Gutierrez, E., Bernhardt, P., Richardson, D., Kalinowski, D. (2013). Alkyl Substituted 2'-Benzoylpyridine Thiosemicarbazone Chelators with Potent and Selective Anti-Neoplastic Activity: Novel Ligands that Limit Methemoglobin Formation. Journal of Medicinal Chemistry, 56(1), 357-370. [More Information]
  • Walcourt, A., Kurantsin-Mills, J., Kwagyan, J., Adenuga, B., Kalinowski, D., Lovejoy, D., Lane, D., Richardson, D. (2013). Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: Effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool. Journal of Inorganic Biochemistry, 129, 43-51. [More Information]
  • Lane, D., Huang, M., Ting, S., Ramesh (Sivagurunathan), S., Richardson, D. (2013). Biochemistry of cardiomyopathy in the mitochondrial disease Friedreich's ataxia. The Biochemical Journal, 453(3), 321-336. [More Information]
  • Merlot, A., Pantarat, N., Menezes, S., Sahni, S., Richardson, D., Kalinowski, D. (2013). Cellular Uptake of the Antitumor Agent Dp44mT Occurs via a Carrier/Receptor-Mediated Mechanism. Molecular Pharmacology, 84(6), 911-924. [More Information]
  • Hua, S., Yao, M., Vignarajan, S., Witting, P., Hejazi, L., Gong, Z., Teng, Y., Niknami, M., Assinder, S., Richardson, D., Dong, Q. (2013). Cytosolic phospholipase A2alpha sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1831 (6), 1146-1157. [More Information]
  • Ford, S., Obeidy, P., Lovejoy, D., Bedford, M., Nichols, L., Chadwick, C., Tucker, O., Lui, G., Kalinowski, D., Jansson, P., Richardson, D., et al (2013). Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. British Journal of Pharmacology, 168(6), 1316-1328. [More Information]
  • Dixon, K., Lui, G., Kovacevic, Z., Zhang, D., Yao, M., Chen, Z., Dong, Q., Assinder, S., Richardson, D. (2013). Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer, 108(2), 409-419. [More Information]
  • Bambang, I., Lee, Y., Richardson, D., Zhang, D. (2013). Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal-epithelial transition in breast cancer cells. Oncogene, 32(10), 1240-1251. [More Information]
  • Huang, M., Austin, C., Sari, M., Suryo Rahmanto, Y., Ponka, P., Vyoral, D., Richardson, D. (2013). Hepcidin Bound to α2-Macroglobulin Reduces Ferroportin-1 Expression and Enhances Its Activity at Reducing Serum Iron Levels. Journal of Biological Chemistry, 288(35), 25450-25465. [More Information]
  • Lane, D., Huang, M., Richardson, D. (2013). Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression. The Biochemical Journal, 452(2), e3-e5. [More Information]
  • Stariat, J., Kovarikova, P., Kucera, R., Klimes, J., Kalinowski, D., Richardson, D., Ketola, R. (2013). Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry. Analytical and Bioanalytical Chemistry, 405(5), 1651-1661. [More Information]
  • Richardson, A., Kovacevic, Z., Richardson, D. (2013). Iron Chelation: Inhibition of Key Signaling Pathways in the Induction of the Epithelial Mesenchymal Transition in Pancreatic Cancer and Other Tumors. Critical Reviews in Oncogenesis, 18(5), 409-434. [More Information]
  • Sun, J., Zhang, D., Bae, D., Sahni, S., Jansson, P., Zheng, Y., Zhao, Q., Yue, F., Zheng, M., Kovacevic, Z., Richardson, D. (2013). Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis, 34(9), 1943-1954. [More Information]
  • Huang, M., Ramesh (Sivagurunathan), S., Ting, S., Jansson, P., Austin, C., Kelly, M., Semsarian, C., Zhang, D., Richardson, D. (2013). Molecular and Functional Alterations in a Mouse Cardiac Model of Friedreich Ataxia: Activation of the Integrated Stress Response, eIF2a Phosphorylation, and the Induction of Downstream Targets. American Journal of Pathology, 183(3), 745-757. [More Information]
  • Stacy, A., Jansson, P., Richardson, D. (2013). Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance. Molecular Pharmacology, 84(5), 655-669. [More Information]
  • Lane, D., Saletta, F., Suryo Rahmanto, Y., Kovacevic, Z., Richardson, D. (2013). N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion. PloS One, 8(2), 1-15. [More Information]
  • Merlot, A., Kalinowski, D., Richardson, D. (2013). Novel Chelators for Cancer Treatment: Where Are We Now? Antioxidants & Redox Signaling, 18(8), 973-1006. [More Information]
  • Yamagishi, T., Sahni, S., Sharp, D., Arvind, A., Jansson, P., Richardson, D. (2013). P-Glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration. Journal of Biological Chemistry, 288(44), 31761-31771. [More Information]
  • Ghalayini, M., Dong, Q., Richardson, D., Assinder, S. (2013). Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells. Bioscience Reports, 33(3), 451-464. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2013). Structure-activity studies of 4-phenyl-substituted 2'-benzoylpyridine thiosemicarbazones with potent and selective anti-tumour activity. Organic and Biomolecular Chemistry, 11(37), 6414-6425. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2013). Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: Novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy. Bioorganic & Medicinal Chemistry Letters, 23(4), 967-974. [More Information]
  • Sun, J., Zhang, D., Zheng, Y., Zhao, Q., Zheng, M., Kovacevic, Z., Richardson, D. (2013). Targeting the Metastasis Suppressor, NDRG1, Using Novel Iron Chelators: Regulation of Stress Fiber-Mediated Tumor Cell Migration via Modulation of the ROCK1/pMLC2 Signaling Pathway. Molecular Pharmacology, 83(2), 454-469. [More Information]
  • Lui, G., Obeidy, P., Ford, S., Tselepis, C., Sharp, D., Jansson, P., Kalinowski, D., Kovacevic, Z., Lovejoy, D., Richardson, D. (2013). The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology, 83(1), 179-190. [More Information]
  • Kovacevic, Z., Chikhani, S., Lui, G., Ramesh (Sivagurunathan), S., Richardson, D. (2013). The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways. Antioxidants & Redox Signaling, 18(8), 874-887. [More Information]
  • Kalinowski, D., Jansson, P., Kovacevic, Z., Richardson, D. (2013). The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. Redox Report, 18(2), 48-50. [More Information]
  • Bae, D., Jansson, P., Huang, M., Kovacevic, Z., Kalinowski, D., Lee, C., Sahni, S., Richardson, D. (2013). The role of NDRG1 in the pathology and potential treatment of human cancers. Journal of Clinical Pathology, 66(11), 911-917. [More Information]
  • Lane, D., Chikhani, S., Richardson, V., Richardson, D. (2013). Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1833 (6), 1527-1541. [More Information]
  • Yu, Y., Suryo Rahmanto, Y., Richardson, D. (2012). Bp44mT: An Orally-Active Iron Chelator of the Thiosemicarbazone Class with Potent Anti-Tumour Efficacy. British Journal of Pharmacology, 165(1), 148-166. [More Information]
  • Debebe, Z., Nekhai, S., Ashenafi, M., Lovejoy, D., Kalinowski, D., Gordeuk, V., Byrnes, W., Richardson, D., Karla, P. (2012). Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 906, 25-32. [More Information]
  • Gao, D., Bambang, I., Putti, T., Lee, Y., Richardson, D., Zhang, D. (2012). ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58(IPK). Laboratory Investigation, 92(2), 200-213. [More Information]
  • Basha, M., Chartres, J., Pantarat, N., Akbar Ali, M., Mirza, A., Kalinowski, D., Richardson, D., Bernhardt, P. (2012). Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity. Dalton Transactions, 41(21), 6536-6548. [More Information]
  • Whitnall, M., Suryo Rahmanto, Y., Huang, M., Saletta, F., Lok, H., Gutierrez, L., Lazaro, F., Fleming, A., ST Pierre, T., Mikhael, M., Richardson, D., et al (2012). Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proceedings of the National Academy of Sciences of the United States of America, 109(50), 20590-20595. [More Information]
  • Brychtova, K., Dvorakova, L., Opatrilova, R., Raich, I., Kacerova, S., Placek, L., Kalinowski, D., Richardson, D., Jampilek, J. (2012). Investigation of substituted 6-aminohexanoates as skin penetration enhancers. Bioorganic and Medicinal Chemistry, 20(1), 86-95. [More Information]
  • Yu, Y., Gutierrez, E., Kovacevic, Z., Saletta, F., Obeidy, P., Suryo Rahmanto, Y., Richardson, D. (2012). Iron chelators for the treatment of cancer. Current Medicinal Chemistry, 19(17), 2689-2702. [More Information]
  • Stariat, J., Sestak, V., Vavrova, K., Nobilis, M., Kollarova, Z., Klimes, J., Kalinowski, D., Richardson, D., Kovarikova, P. (2012). LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT. Analytical and Bioanalytical Chemistry, 403(1), 309-321. [More Information]
  • Suryo Rahmanto, Y., Bal, S., Loh, K., Yu, Y., Richardson, D. (2012). Melanotransferrin: Search for a function. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1820 (3), 237-243. [More Information]
  • Quach, P., Gutierrez, E., Basha, M., Kalinowski, D., Sharpe, P., Lovejoy, D., Bernhardt, P., Jansson, P., Richardson, D. (2012). Methemoglobin Formation by Triapine, Di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone (Dp44mT), and Other Anticancer Thiosemicarbazones: Identification of Novel Thiosemicarbazones and Therapeutics That Prevent This Effect. Molecular Pharmacology, 82(1), 105-114. [More Information]
  • Lok, H., Suryo Rahmanto, Y., Hawkins, C., Kalinowski, D., Morrow, C., Townsend, A., Ponka, P., Richardson, D. (2012). Nitric oxide storage and transport in cells are mediated by glutathione S-transferase P1-1 and Multidrug Resistant Protein 1 via Dinitrosyl iron complexes. Journal of Biological Chemistry, 287(1), 607-618. [More Information]
  • Suryo Rahmanto, Y., Kalinowski, D., Lane, D., Lok, H., Richardson, V., Richardson, D. (2012). Nitrogen Monoxide (NO) Storage and Transport by Dinitrosyl-Dithiol-Iron Complexes: Long-Lived NO that is Trafficked by Interacting Proteins. Journal of Biological Chemistry, 287(10), 6960-6968. [More Information]
  • Lovejoy, D., Sharp, D., Seebacher, N., Obeidy, P., Prichard, T., Stefani, C., Basha, M., Sharpe, P., Jansson, P., Kalinowski, D., Richardson, D., et al (2012). Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo. Journal of Medicinal Chemistry, 55(16), 7230-7244. [More Information]
  • Correnti, C., Richardson, V., Sia, A., Bandaranayake, A., Ruiz, M., Suryo Rahmanto, Y., Kovacevic, Z., Clifton, M., Holmes, M., Kaiser, B., Richardson, D., et al (2012). Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines. PloS One, 7(8), 1-15. [More Information]
  • Li, C., Lonn, M., Xu, X., Maghzal, G., Frazer, D., Thomas, S., Halliwell, B., Richardson, D., Anderson, G., Stocker, R. (2012). Sustained expression of heme oxygenase-1 alters iron homeostasis in nonerythroid cells. Free Radical Biology and Medicine, 53(2), 366-374. [More Information]
  • Serda, M., Kalinowski, D., Mrozek-Wilczkiewicz, A., Musiol, R., Szurko, A., Ratuszna, A., Pantarat, N., Kovacevic, Z., Merlot, A., Richardson, D., et al (2012). Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorganic & Medicinal Chemistry Letters, 22(17), 5527-5531. [More Information]
  • Kovacevic, Z., Richardson, D. (2012). Targeting Iron in Cancer Cells: A New Strategy to Inhibit Metastatic Progression. Vitamins & Trace Elements, 1(3), 1-2. [More Information]
  • Chen, Z., Zhang, D., Yue, F., Zheng, M., Kovacevic, Z., Richardson, D. (2012). The iron chelators Dp44mT and DFO inhibit TGF-B-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). Journal of Biological Chemistry, 287(21), 17016-17028. [More Information]
  • Lovejoy, D., Jansson, P., Brunk, U., Wong, J., Ponka, P., Richardson, D. (2011). Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes. Cancer Research, 71(17), 5871-5880. [More Information]
  • Saletta, F., Suryo Rahmanto, Y., Siafakas, A., Richardson, D. (2011). Cellular Iron Depletion and the Mechanisms involved in the Iron-dependent Regulation of the Growth Arrest and DNA Damage Family of Genes. Journal of Biological Chemistry, 286(41), 35396-35406. [More Information]
  • Yu, Y., Richardson, D. (2011). Cellular Iron Depletion Stimulates the JNK and p38 MAPK Signaling Transduction Pathways, Dissociation of ASK1-Thioredoxin, and Activation of ASK1. Journal of Biological Chemistry, 286(17), 15413-15427. [More Information]
  • Kovacevic, Z., Yu, Y., Richardson, D. (2011). Chelators to the rescue: different horses for different courses!. Chemical Research in Toxicology, 24(3), 279-282. [More Information]
  • Zhang, D., Richardson, D. (2011). Endoplasmic reticulum protein 29 (ERp29): An emerging role in cancer. The International Journal of Biochemistry and Cell Biology, 43(1), 33-36. [More Information]
  • Stefani, C., Punnia-Moorthy, G., Lovejoy, D., Jansson, P., Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2011). Halogenated 2'-Benzoylpyridine Thiosemicarbazone (XBpT) Chelators with Potent and Selective Anti-Neoplastic Activity: Relationship to Intracellular Redox Activity. Journal of Medicinal Chemistry, 54(19), 6936-6948. [More Information]
  • Saletta, F., Kovacevic, Z., Richardson, D. (2011). Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules. Future Medicinal Chemistry, 3(16), 1983-1986. [More Information]
  • Debebe, Z., Ammosova, T., Breuer, D., Lovejoy, D., Kalinowski, D., Karla, P., Kumar, K., Jarebtsova, M., Ray, P., Kashanchi, F., Richardson, D., et al (2011). Iron Chelators of the Di-2-pyridylketone Thiosemicarbazone and 2-Benzoylpyridine Thiosemicarbazone Series Inhibit HIV-1 Transcription: Identification of Novel Cellular Targets-Iron, Cyclin-Dependent Kinase (CDK) 2, and CDK9. Molecular Pharmacology, 79(1), 185-196. [More Information]
  • Bernhardt, P., Richardson, D. (2011). Metal chelation. Current Topics in Medicinal Chemistry, 11(5), 482-482. [More Information]
  • Huang, M., Lane, D., Richardson, D. (2011). Mitochondrial Mayhem: The Mitochondrion as a Modulator of Iron Metabolism and Its Role in Disease. Antioxidants & Redox Signaling, 15(12), 3003-3019. [More Information]
  • Kovacevic, Z., Chikhani, S., Lovejoy, D., Richardson, D. (2011). Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A new Strategy for the Treatment of Pancreatic Cancer. Molecular Pharmacology, 80(4), 598-609. [More Information]
  • Sharpe, P., Richardson, D., Kalinowski, D., Bernhardt, P. (2011). Synthetic and natural products as iron chelators. Current Topics in Medicinal Chemistry, 11(5), 591-607. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Yu, Y., Suryo Rahmanto, Y., Sharpe, P., Bernhardt, P., Richardson, D. (2011). The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Current Topics in Medicinal Chemistry, 11(5), 483-499. [More Information]
  • Kovacevic, Z., Ramesh (Sivagurunathan), S., Mangs, A., Chikhani, S., Zhang, D., Richardson, D. (2011). The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis, 32(5), 732-740. [More Information]
  • Yu, Y., Suryo Rahmanto, Y., Hawkins, C., Richardson, D. (2011). The Potent and Novel Thiosemicarbazone Chelators Di-2- pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2- Benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity. Molecular Pharmacology, 79(6), 921-931. [More Information]
  • Miao, Q., Xu, D., Wang, Z., Xu, L., Wang, T., Wu, Y., Lovejoy, D., Kalinowski, D., Richardson, D., Nie, G., et al (2010). Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents. Biomaterials, 31(28), 7364-7375. [More Information]
  • Bendova, P., Mackova, E., Haskova, P., Vavrova, A., Jirkovsky, E., Sterba, M., Popelova, O., Kalinowski, D., Kovarikova, P., Vavrova, K., Richardson, D., et al (2010). Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 23(6), 1105-1114. [More Information]
  • Liu, J., Obando Gutierrez, D., Schipanski, L., Groebler, L., Witting, P., Kalinowski, D., Richardson, D., Codd, R. (2010). Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron Overload. Journal of Medicinal Chemistry, 53(3), 1370-1382. [More Information]
  • Stariat, J., Kovarikova, P., Klimes, J., Kalinowski, D., Richardson, D. (2010). Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT. Analytical and Bioanalytical Chemistry, 397(1), 161-171. [More Information]
  • Lane, D., Richardson, D. (2010). Frataxin, a molecule of mystery: trading stability for function in its iron-binding site. Biochemical Journal, 426(2), e1-e3. [More Information]
  • Brychtova, K., Opatrilova, R., Raich, I., Kalinowski, D., Dvorakova, L., Placek, L., Csollei, J., Richardson, D., Jampilek, J. (2010). Investigating the activity of 2-substituted alkyl-6-(25-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers. Bioorganic and Medicinal Chemistry, 18(24), 8556-8565. [More Information]
  • Mrozek-Wilczkiewicz, A., Kalinowski, D., Musiol, R., Finster, J., Szurko, A., Serafin, K., Knas, M., Kamalapuram, S., Kovacevic, Z., Jampilek, J., Richardson, D., et al (2010). Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones. Bioorganic and Medicinal Chemistry, 18(7), 2664-2671. [More Information]
  • Otevrel, J., Mandelova, Z., Pesko, M., Guo, J., Kralova, K., Sersen, F., Vejsova, M., Kalinowski, D., Kovacevic, Z., Coffey, A., Richardson, D., et al (2010). Investigating the Spectrum of Biological Activity of Ring-Substituted Salicylanilides and Carbamoylphenylcarbamates. Molecules, 15(11), 8122-8142. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Quach, P., Burn (Wong), J., Richardson, D. (2010). Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Current Drug Delivery, 7(3), 194-207. [More Information]
  • Merlot, A., Pantarat, N., Lovejoy, D., Kalinowski, D., Richardson, D. (2010). Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer. Molecular Pharmacology, 78(4), 675-684. [More Information]
  • Richardson, D., Lane, D., Becker, E., Huang, M., Suryo Rahmanto, Y., Sheftel, A., Ponka, P. (2010). Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proceedings of the National Academy of Sciences of the United States of America, 107(24), 10775-10782. [More Information]
  • Jansson, P., Sharpe, P., Bernhardt, P., Richardson, D. (2010). Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity. Journal of Medicinal Chemistry, 53(15), 5759-5769. [More Information]
  • Singleton, W., McInnes, K., Cater, M., Winnall, W., McKirdy, R., Yu, Y., Taylor, P., Ke, B., Richardson, D., Mercer, J., et al (2010). Role of Glutaredoxin1 and Glutathione in Regulating the Activity of the Copper-transporting P-type ATPases, ATP7A and ATP7B. Journal of Biological Chemistry, 285, 27111-27121. [More Information]
  • Richardson, D., Huang, M., Whitnall, M., Becker, E., Ponka, P., Suryo Rahmanto, Y. (2010). The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. Journal of Molecular Medicine, 88(4), 323-329. [More Information]
  • Jansson, P., Hawkins, C., Lovejoy, D., Richardson, D. (2010). The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study. Journal of Inorganic Biochemistry, 104(11), 1224-1228. [More Information]
  • Saletta, F., Suryo Rahmanto, Y., Richardson, D. (2010). The Translational Regulator eIF3a: The Tricky eIF3 Subunit!. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1806 (2), 275-86. [More Information]
  • Richardson, D., Kalinowski, D., Richardson, V., Sharpe, P., Lovejoy, D., Islam, M., Bernhardt, P. (2009). 2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity. Journal of Medicinal Chemistry, 52(5), 1459-1470. [More Information]
  • Noulsri, E., Richardson, D., Lerdwana, S., Fucharoen, S., Yamagishi, T., Kalinowski, D., Pattanapanyasat, K. (2009). Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. American Journal Of Hematology, 84(3), 170-176. [More Information]
  • Bohlken, A., Cheung, B., Bell, J., Koach, J., Smith, S., Sekyere, E., Thomas, W., Norris, M., Lovejoy, D., Richardson, D. (2009). ATP7A is a novel target of retinoic acid receptor β2 in neuroblastoma cells. British Journal of Cancer, 100(1), 96-105. [More Information]
  • Richardson, D., Kalinowski, D., Lau, S., Jansson, P., Lovejoy, D. (2009). Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochimica et Biophysica Acta, 1790 (7), 702-717. [More Information]
  • Huang, M., Becker, E., Whitnall, M., Suryo Rahmanto, Y., Ponka, P., Richardson, D. (2009). Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proceedings of the National Academy of Sciences of the United States of America, 106(38), 16381-16386. [More Information]
  • Suryo Rahmanto, Y., Richardson, D. (2009). Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype. Biochimica et Biophysica Acta, 1793 (7), 1210-1217. [More Information]
  • Siafakas, A., Richardson, D. (2009). Growth arrest and DNA damage-45 alpha (GADD45alpha). The International Journal of Biochemistry and Cell Biology, 41(5), 986-989. [More Information]
  • Peslova, G., Petrak, J., Kuzelova, K., Hrdy, I., Halada, P., Kuchel, P., Soe-Lin, S., Ponka, P., Sutak, R., Becker, E., Huang, M., Suryo Rahmanto, Y., Richardson, D., Vyoral, D. (2009). Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood, 113(24), 6225-6236. [More Information]
  • Stariat, J., Kovarikova, P., Klimes, J., Lovejoy, D., Kalinowski, D., Richardson, D. (2009). HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 877(3), 316-322. [More Information]
  • Saletta, F., Suryo Rahmanto, Y., Noulsri, E., Richardson, D. (2009). Iron Chelator-Mediated Alterations in Gene Expression: Identification of Novel Iron-Regulated Molecules that are Molecular Targets of HIF-1{alpha} and p53. Molecular Pharmacology, 77(3), 443-458. [More Information]
  • Bernhardt, P., Sharpe, P., Islam, M., Lovejoy, D., Kalinowski, D., Richardson, D. (2009). Iron Chelators of the Dipyridylketone Thiosemicarbazone Class: Precomplexation and Transmetalation Effects on Anticancer Activity. Journal of Medicinal Chemistry, 52(2), 407-415. [More Information]
  • Sheftel, A., Richardson, D., Prchal, J., Ponka, P. (2009). Mitochondrial Iron Metabolism and Sideroblastic Anemia. Acta Haematologica, 122(2-3), 120-133. [More Information]
  • Assinder, S., Dong, Q., Mangs, A., Richardson, D. (2009). Pharmacological targeting of the integrated protein kinase B, phosphatase and tensin homolog deleted on chromosome 10, and transforming growth Factor-β pathways in prostate cancer. Molecular Pharmacology, 75(3), 429-436. [More Information]
  • Mladenka, P., Kalinowski, D., Haskova, P., Bobrovova, Z., Hrdina, R., Simunek, T., Nachtigal, P., Semecky, V., Vavrova, J., Holeckova, M., Jansson, P., Richardson, D., et al (2009). The Novel Iron Chelator, 2-Pyridylcarboxaldehyde 2-Thiophenecarboxyl Hydrazone, Reduces Catecholamine-Mediated Myocardial Toxicity. Chemical Research in Toxicology, 22(1), 208-217. [More Information]
  • Assinder, S., Dong, Q., Kovacevic, Z., Richardson, D. (2009). The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal, 417(2), 411-421. [More Information]
  • Yu, Y., Kalinowski, D., Kovacevic, Z., Siafakas, A., Jansson, P., Stefani, C., Lovejoy, D., Sharpe, P., Bernhardt, P., Richardson, D. (2009). Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. Journal of Medicinal Chemistry, 52(17), 5271-5294. [More Information]
  • Kalinowski, D., Quach, P., Richardson, D. (2009). Thiosemicarbazones: the new wave in cancer treatment. Future Medicinal Chemistry, 1(6), 1143-1151. [More Information]
  • Long, S., Jirku, M., Mach, J., Ginger, M., Sutak, R., Richardson, D., Tachezy, J., Lukes, J. (2008). Ancestral roles of eukaryotic frataxin: mitochondrial frataxin function and heterologous expression of hydrogenosomal Trichomonas homologues in trypanosomes. Molecular Microbiology, 69(1), 94-109. [More Information]
  • Farnaud, S., Amini, M., Rapisarda, C., Cammack, R., Bui, T., Drake, A., Evans, R., Suryo Rahmanto, Y., Richardson, D. (2008). Biochemical and spectroscopic studies of human melanotransferrin (MTf): Electron-paramagnetic resonance evidence for a difference between the iron-binding site of MTf and other transferrins. The International Journal of Biochemistry and Cell Biology, 40(12), 2739-2745. [More Information]
  • Sutak, R., Lesuisse, E., Tachezy, J., Richardson, D. (2008). Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends in Microbiology, 16(6), 261-8. [More Information]
  • Opletalova, V., Kalinowski, D., Vesjova, M., Kunes, J., Pour, M., Jampılek, J., Buchta, V., Richardson, D. (2008). Identification and Characterization of Thiosemicarbazones with Antifungal and Antitumor Effects: Cellular Iron Chelation Mediating Cytotoxic Activity. Chemical Research in Toxicology, 21(9), 1878-1889. [More Information]
  • Xu, X., Sutak, R., Richardson, D. (2008). Iron Chelation by Clinically Relevant Anthracyclines: Alteration in Expression of Iron-Regulated Genes and Atypical Changes in Intracellular Iron Distribution and Trafficking. Molecular Pharmacology, 73(3), 833-844. [More Information]
  • Lim, C., Kalinowski, D., Richardson, D. (2008). Protection Against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich's Ataxia Fibroblasts using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class. Molecular Pharmacology, 74(1), 225-235. [More Information]
  • Sutak, R., Xu, X., Whitnall, M., Kashem, M., Vyoral, D., Richardson, D. (2008). Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism. Proteomics, 8, 1731-1741. [More Information]
  • Lim, S., Raftery, M., Cai, H., Hsu, K., Yan, W., Hseih, H., Watts, R., Richardson, D., Thomas, S., Perry, M., et al (2008). S-nitrosylated S100A8: novel anti-inflammatory properties. Journal of Immunology, 181(8), 5627-5636. [More Information]
  • Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2008). Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. Journal of Medicinal Chemistry, 51(2), 331-344. [More Information]
  • Kovacevic, Z., Fu, D., Richardson, D. (2008). The iron-regulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets. Biochimica et Biophysica Acta, 1783 (10), 1981-1992. [More Information]
  • Whitnall, M., Suryo Rahmanto, Y., Sutak, R., Xu, X., Becker, E., Mikhael, M., Ponka, P., Richardson, D. (2008). The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proceedings of the National Academy of Sciences of the United States of America, 105(28), 9757-9762. [More Information]
  • Richardson, D., Lok, H. (2008). The nitric oxide-iron interplay in mammalian cells: transport and storage of dinitrosyl iron complexes. Biochimica et Biophysica Acta, 1780 (4), 638-651. [More Information]
  • Bernhardt, P., Wilson, G., Sharpe, P., Kalinowski, D., Richardson, D. (2008). Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. Journal of Biological Inorganic Chemistry, 13(1), 107-119. [More Information]
  • Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2007). Design, Synthesis, and Characterization of New Iron Chelators with Anti-Proliferative Activity: Structure-Activity Relationships of Novel Thiohydrazone Analogues. Journal of Medicinal Chemistry, 50(24), 6212-6225. [More Information]
  • Kalinowski, D., Yu, Y., Sharpe, P., Islam, M., Liao, Y., Lovejoy, D., Kumar, N., Bernhardt, P., Richardson, D. (2007). Design, Synthesis, and Characterization of Novel Iron Chelators: Structure-Activity Relationships of the 2-Benzoylpyridine Thiosemicarbazone Series and Their 3-Nitrobenzoyl Analogues as Potent Antitumor Agents. Journal of Medicinal Chemistry, 50(15), 3716-3729. [More Information]
  • Mrkvicková, Z., Kovaríková, P., Klimes, J., Kalinowski, D., Richardson, D. (2007). Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity. Journal of Pharmaceutical and Biomedical Analysis, 43(4), 1343-1351. [More Information]
  • Richardson, D., Suryo Rahmanto, Y. (2007). Differential regulation of the Menkes and Wilson disease copper transporters by hormones: an integrated model of metal transport in the placenta. Biochemical Journal, 402(2), e1-e3. [More Information]
  • Kalinowski, D., Richardson, D. (2007). Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chemical Research in Toxicology, 20(5), 715-720. [More Information]
  • Bernhardt, P., Chin, P., Sharpe, P., Richardson, D. (2007). Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity. Dalton Transactions, 30, 3232-3244. [More Information]
  • Suryo Rahmanto, Y., Dunn, L., Richardson, D. (2007). Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo. Carcinogenesis, 28(10), 2172-2183. [More Information]
  • Musiol, R., Jampilek, J., Kralova, K., Richardson, D., Kalinowski, D., Podeszwa, B., Finster, J., Niedbala, H., Palka, A., Polanski, J. (2007). Investigating biological activity spectrum for novel quinoline analogues. Bioorganic and Medicinal Chemistry, 15(3), 1280-1288. [More Information]
  • Podeszwa, B., Niedbala, H., Polanski, J., Musiol, R., Tabak, D., Finster, J., Serafin, K., Milczarek, M., Wietrzyk, J., Boryczka, S., Kalinowski, D., Richardson, D., et al (2007). Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. Bioorganic and Medicinal Chemistry Letters, 17(22), 6138-6141. [More Information]
  • Podeszwa, B., Niedbala, H., Polanski, J., Musiol, R., Tabak, D., Finster, J., Serafin, K., Milczarek, M., Wietrzyk, J., Boryczka, S., Kalinowski, D., Richardson, D., et al (2007). Investigating the antiproliferative and styrylquinolinecarboxyli activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. Bioorganic and Medicinal Chemistry Letters, 17(22), 6138-6141. [More Information]
  • Fu, D., Richardson, D. (2007). Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood, 110(2), 752-761. [More Information]
  • Nurtjahja-Tjendraputra, E., Fu, D., Phang, J., Richardson, D. (2007). Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood, 109(9), 4045-4054.
  • Debebe, Z., Ammosova, T., Jerebtsova, M., Kurantsin-Mills, J., Niu, X., Charles, S., Richardson, D., Ray, P., Gordeuk, V., Nekhai, S. (2007). Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology, 367(2), 324-333. [More Information]
  • Suryo Rahmanto, Y., Dunn, L., Richardson, D. (2007). The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark - from iron metabolism to tumorigenesis. Oncogene, 26(42), 6113-6124. [More Information]
  • Yu, Y., Kovacevic, Z., Richardson, D. (2007). Tuning Cell Cycle Regulation With an Iron Key. Cell Cycle, 6(16), 1982-1994. [More Information]
  • Whitnall, M., Howard, J., Ponka, P., Richardson, D. (2006). A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proceedings of the National Academy of Sciences of the United States of America, 103(40), 14901-14906. [More Information]
  • Yu, Y., Wong, J., Lovejoy, D., Kalinowski, D., Richardson, D. (2006). Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clinical Cancer Research, 12(23), 6876-6883. [More Information]
  • Richardson, D., Sharpe, P., Lovejoy, D., Senaratne, D., Kalinowski, D., Islam, M., Bernhardt, P. (2006). Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity. Journal of Medicinal Chemistry, 49(22), 6510-6521. [More Information]
  • Suryo Rahmanto, Y., Richardson, D., Dunne, L., Sekyere, E. (2006). Identification of melanotransferin (p97) associated genes using in vitro and in vivo models. Free Radical Research, 40, S55.
  • Nurtjahja-Tjendraputra, E., Fu, D., Phang, J., Richardson, D. (2006). Iron Chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood, 109(9), 4045-4054. [More Information]
  • Richardson, D., Lovejoy, D. (2006). Iron mining" if to inhibit tumor growth.". Blood, 108(7), 2140-2140.
  • Dunn, L., Suryo Rahmanto, Y., Richardson, D. (2006). Iron uptake and metabolism in the new millennium. Trends in Cell Biology, 17(2), 93-100. [More Information]
  • Whitnall, M., Richardson, D. (2006). Iron: a new target for pharmacological intervention in neurodegenerative diseases. Seminars in Pediatric Neurology, 13(3), 186-97. [More Information]
  • Watts, R., Hawkins, C., Ponka, P., Richardson, D. (2006). Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proceedings of the National Academy of Sciences of the United States of America, 103(20), 7670-7675. [More Information]
  • Lovejoy, D., Kalinowski, D., Bernhardt, P., Richardson, D. (2006). PCTH: A Novel Orally Active Chelator for the Treatment of Iron Overload Disease. Hemoglobin, 30(1), 93-104. [More Information]
  • Davies, N., Suryo Rahmanto, Y., Chitambar, C., Richardson, D. (2006). Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates. Journal of Pharmacology and Experimental Therapeutics, 317(1), 153-162. [More Information]
  • Owusu Sekyere, E., Dunn, L., Suryo Rahmanto, Y., Richardson, D. (2006). Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood, 107(7), 2599-2601. [More Information]
  • Sekyere, E., Dunn, L., Suryo Rahmanto, Y., Richardson, D. (2006). Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood, 107(6), 2599-2601. [More Information]
  • Dunn, L., Owusu Sekyere, E., Suryo Rahmanto, Y., Richardson, D. (2006). The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis, 27(11), 2157-2169. [More Information]
  • Dunn, L., Sekyere, E., Rahmanto, Y., Richardson, D. (2006). The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis, 27(11), 2157-2169. [More Information]
  • Kovacevic, Z., Richardson, D. (2006). The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 27(12), 2355-2366. [More Information]
  • Napier, I., Ponka, P., Richardson, D. (2005). Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood, 105(5), 1867-74. [More Information]
  • Kalinowski, D., Richardson, D. (2005). The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharmacological Reviews, 57(4), 547-583. [More Information]
  • Bernhardt, P., Caldwell, L., Lovejoy, D., Richardson, D. (2003). Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta Crystallographica. Section C: Crystal Structure Communications, 59(11), o629-o633. [More Information]
  • Becker, E., Lovejoy, D., Greer, J., Watts, R., Richardson, D. (2003). Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. British Journal of Pharmacology, 138(5), 819-830. [More Information]
  • Thomas, S., Salahifar, H., Mashima, R., Hunt, N., Richardson, D., Stocker, R. (2001). Antioxidants Inhibit Indoleamine 2,3-Dioxygenase in IFN-gamma-Activated Human Macrophages: Posttranslational Regulation by Pyrrolidine Dithiocarbamate. Journal of Immunology, 166, 6332-6340.

Conferences

  • Nurtjahja-Tjendraputra, E., Fu, D., Phang, J., Richardson, D. (2006). Cellular Iron Levels Regulate Cyclin D1 Expression via the Proteasome: a Link to Iron-Depletion Mediated Grwoth Suppression. The Young Investigators Symposium.
  • Fu, D., Richardson, D. (2005). Iron-dependent regulation of the cell cycle: the expression of the universal cyclin-dependent kinase inhibitor p21(cipl/wafl) after iron chelation. BioIron 2005, Prague.
  • Fu, D., Richardson, D. (2005). The cyclin-dependent kinast inhibitor p21CIPI/WAF1 is degraded by the proteasomal pathway after iron chelation. Seventh Annual MEPSA Scientific Conference.
  • Little, C., Cramp, J., Curtis, C., Richardson, D., Schoenherr, B., Innes, J., Jones, S., Caterson, B. (2003). Canine articular catilage degradation: The role of catabolic cytokines. 49th Annual Meeting of the Orthopaedic Research Society, United states: Orthopaedic Research Society.

2018

  • Lane, D., Bae, D., Siafakas, A., Rahmanto, Y., Al-Akra, L., Jansson, P., Casero Jr., R., Richardson, D. (2018). Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1864 (9 Part B), 2793-2813. [More Information]
  • Park, K., Menezes, S., Kalinowski, D., Sahni, S., Jansson, P., Kovacevic, Z., Richardson, D. (2018). Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1864 (8), 2644-2663. [More Information]
  • Richardson, D. (2018). Laying Down a Solid �Iron Foundation�: Professor Erica Baker. Biochimica et Biophysica Acta - General Subjects, 1862 (10), e1-e2. [More Information]
  • Chiang, S., Kalinowski, D., Jansson, P., Richardson, D., Huang, M. (2018). Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia. Neurochemistry International, 117, 35-48. [More Information]
  • Palanimuthu, D., Wu, Z., Jansson, P., Braidy, N., Bernhardt, P., Richardson, D., Kalinowski, D. (2018). Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease. Dalton Transactions, 47(21), 7190-7205. [More Information]
  • Bae, D., Lane, D., Jansson, P., Richardson, D. (2018). The old and new biochemistry of polyamines. Biochimica et Biophysica Acta - General Subjects, 1862 (9), 2053-2068. [More Information]
  • Saleh Moussa, R., Kovacevic, Z., Bae, D., Lane, D., Richardson, D. (2018). Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21(CIP1/WAF1), by the chelator, Dp44mT. Biochimica et Biophysica Acta - General Subjects, 1862 (3), 761-774. [More Information]
  • Al-Akra, L., Bae, D., Sahni, S., Huang, M., Park, K., Lane, D., Jansson, P., Richardson, D. (2018). Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones. Journal of Biological Chemistry, 293(10), 3562-3587. [More Information]

2017

  • Palanimuthu, D., Poon, R., Sahni, S., Anjum, R., Hibbs, D., Lin, H., Bernhardt, P., Kalinowski, D., Richardson, D. (2017). A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 139, 612-632. [More Information]
  • Menezes, S., Sahni, S., Kovacevic, Z., Richardson, D. (2017). Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling. Journal of Biological Chemistry, 292(31), 12772-12782. [More Information]
  • Fouani, L., Menezes, S., Paulson, M., Richardson, D., Kovacevic, Z. (2017). Metals and metastasis: Exploiting the role of metals in cancer metastasis to develop novel anti-metastatic agents. Pharmacological Research, 115, 275-287. [More Information]
  • Anzovino, A., Chiang, S., Brown, B., Hawkins, C., Richardson, D., Huang, M. (2017). Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3(beta) Axis. American Journal of Pathology, 187(12), 2858-2875. [More Information]
  • Shi, L., Ito, F., Wang, Y., Okazaki, Y., Tanaka, H., Mizuno, M., Hori, M., Hirayama, T., Nagasawa, H., Richardson, D., Toyokuni, S. (2017). Non-thermal plasma induces a stress response in mesothelioma cells resulting in increased endocytosis, lysosome biogenesis and autophagy. Free Radical Biology and Medicine, 108, 904-917. [More Information]
  • Xi, R., Pun, I., Menezes, S., Fouani, L., Kalinowski, D., Huang, M., Zhang, X., Richardson, D., Kovacevic, Z. (2017). Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1). Molecular Pharmacology, 91(5), 499-517. [More Information]
  • Kovacevic, Z., Sahni, S., Lok, H., Davies, M., Wink, D., Richardson, D. (2017). Regulation and control of nitric oxide (NO) in macrophages: Protecting the "professional killer cell" from its own cytotoxic arsenal via MRP1 and GSTP1. Biochimica et Biophysica Acta - General Subjects, 1861 (5), 995-999. [More Information]
  • Yanatori, I., Richardson, D., Toyokuni, S., Kishi, F. (2017). The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer. Journal of Biological Chemistry, 292(32), 13205-13229. [More Information]
  • Sahni, S., Bae, D., Jansson, P., Richardson, D. (2017). The mechanistic role of chemically diverse metal ions in the induction of autophagy. Pharmacological Research, 119, 118-127. [More Information]

2016

  • Seebacher, N., Richardson, D., Jansson, P. (2016). A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death and Disease, 7(12), 1-13. [More Information]
  • Lok, H., Sahni, S., Jansson, P., Kovacevic, Z., Hawkins, C., Richardson, D. (2016). A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity. Journal of Biological Chemistry, 291(53), 27042-27061. [More Information]
  • Shi, L., Wang, Y., Ito, F., Okazaki, Y., Tanaka, H., Mizuno, M., Hori, M., Richardson, D., Toyokuni, S. (2016). Biphasic effects of l-ascorbate on the tumoricidal activity of non-thermal plasma against malignant mesothelioma cells. Archives of Biochemistry and Biophysics, 605, 109-116. [More Information]
  • Lane, D., Jansson, P., Richardson, D. (2016). Bonnie and Clyde: Vitamin C and iron are partners in crime in iron deficiency anaemia and its potential role in the elderly. Aging, 8(5), 1150-1152. [More Information]
  • Park, K., Fouani, L., Jansson, P., Wooi, D., Sahni, S., Lane, D., Palanimuthu, D., Lok, H., Kovacevic, Z., Huang, M., Kalinowski, D., Richardson, D. (2016). Copper and conquer: Copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics. Metallomics, 8(9), 874-886. [More Information]
  • Kovacevic, Z., Sahni, S., Richardson, D. (2016). Copper that cancer with lysosomal love!. Aging, 8(2), 210-211. [More Information]
  • Chiang, S., Kovacevic, Z., Sahni, S., Lane, D., Merlot, A., Kalinowski, D., Huang, M., Richardson, D. (2016). Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia. Clinical Science, 130(11), 853-870. [More Information]
  • Seebacher, N., Lane, D., Jansson, P., Richardson, D. (2016). Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter. Journal of Biological Chemistry, 291(8), 3796-3820. [More Information]
  • Klionsky, D., Abdelmohsen, K., Akihisa, A., Abedin, M., Abeliovich, H., Acevedo-Arozena, A., Arozena, H., Adams, C., Adams, P., et al, Sue, C., Mihailidou, A., Bae, D., Gutierrez, E., Jansson, P., Lane, D., Merlot, A., Richardson, D., Sahni, S. (2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 12(1), 1-222. [More Information]
  • Yanatori, I., Richardson, D., Imada, K., Kishi, F. (2016). Iron export through the transporter ferroportin 1 is modulated by the iron chaperone PCBP2. Journal of Biological Chemistry, 291(33), 17303-17318. [More Information]
  • Basha, M., Bordini, J., Richardson, D., Martinez, M., Bernhardt, P. (2016). Kinetico-mechanistic studies on methemoglobin generation by biologically active thiosemicarbazone iron(III) complexes. Journal of Inorganic Biochemistry, 162, 326-333. [More Information]
  • Merlot, A., Sahni, S., Lane, D., Richardson, V., Huang, M., Kalinowski, D., Richardson, D. (2016). Letter to the Editor: Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques"". International Journal of Molecular Sciences, 17(11), E1916. [More Information]
  • Yingchoncharoen, P., Kalinowski, D., Richardson, D. (2016). Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacological Reviews, 68(3), 701-787. [More Information]
  • Gutierrez, E., Seebacher, N., Arzuman, L., Kovacevic, Z., Lane, D., Richardson, V., Merlot, A., Lok, H., Kalinowski, D., Sahni, S., Jansson, P., Richardson, D. (2016). Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT). Biochimica et Biophysica Acta, 1863 (7 Pt A), 1665-1681. [More Information]
  • Merlot, A., Shafie, N., Yu, Y., Richardson, V., Jansson, P., Sahni, S., Lane, D., Kovacevic, Z., Kalinowski, D., Richardson, D. (2016). Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2[alpha], IRE1[alpha], ATF6 and calmodulin kinase. Biochemical Pharmacology, 109, 27-47. [More Information]
  • Al-Eisawi, Z., Stefani, C., Jansson, P., Arvind, A., Sharpe, P., Basha, M., Iskander, G., Kumar, N., Kovacevic, Z., Lane, D., Sahni, S., Richardson, D., Kalinowski, D., et al (2016). Novel Mechanism of Cytotoxicity for the Selective Selenosemicarbazone, 2-Acetylpyridine 4,4-Dimethyl-3- selenosemicarbazone (Ap44mSe): Lysosomal Membrane Permeabilization. Journal of Medicinal Chemistry, 59(1), 294-312. [More Information]
  • Cahill, M., Jazayeri, J., Kovacevic, Z., Richardson, D. (2016). PGRMC1 regulation by phosphorylation: Potential new insights in controlling biological activity!. Oncotarget, 7(32), 50822-50827. [More Information]
  • Paluncic, J., Kovacevic, Z., Jansson, P., Kalinowski, D., Merlot, A., Huang, M., Lok, H., Sahni, S., Lane, D., Richardson, D. (2016). Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. Biochimica et Biophysica Acta, 1863 (4), 770-784. [More Information]
  • Stacy, A., Palanimuthu, D., Bernhardt, P., Kalinowski, D., Jansson, P., Richardson, D. (2016). Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance. Journal of Medicinal Chemistry, 59(18), 8601-8620. [More Information]
  • Sahni, S., Kovacevic, Z., Kalinowski, D., Huang, M., Menezes, S., Krishan, S., Lane, D., Jansson, P., Richardson, D. (2016). Targeting autophagy in antitumor agent design: Furthering the 'lysosomal love' strategy. Future Medicinal Chemistry, 8(7), 727-729. [More Information]
  • Wangpu, X., Lu, J., Xi, R., Yue, F., Sahni, S., Park, K., Menezes, S., Huang, M., Zheng, M., Kovacevic, Z., Richardson, D. (2016). Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling. Molecular Pharmacology, 89(5), 521-540. [More Information]
  • Krishan, S., Richardson, D., Sahni, S. (2016). The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells. Biochimica et Biophysica Acta, 1863 (12), 2916-2933. [More Information]
  • Cahill, M., Jazayeri, J., Catalano, S., Toyokuni, S., Kovacevic, Z., Richardson, D. (2016). The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochimica et Biophysica Acta, 1866 (2), 339-349. [More Information]
  • Kovacevic, Z., Menezes, S., Sahni, S., Kalinowski, D., Bae, D., Lane, D., Richardson, D. (2016). The metastasis suppressor, N-MYC downstream-regulated gene-1 (NDRG1), down-regulates the ErbB family of receptors to inhibit downstream oncogenic signaling pathways. Journal of Biological Chemistry, 291(3), 1029-1052. [More Information]
  • Guo, Z., Richardson, D., Kalinowski, D., Kovacevic, Z., Tan-Un, K., Chan, G. (2016). The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. Journal of Hematology and Oncology, 9(1), 1-16. [More Information]
  • Seebacher, N., Lane, D., Richardson, D., Jansson, P. (2016). Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance. Free Radical Biology and Medicine, 96, 432-445. [More Information]
  • Stacy, A., Palanimuthu, D., Bernhardt, P., Kalinowski, D., Jansson, P., Richardson, D. (2016). Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity. Journal of Medicinal Chemistry, 59(10), 4965-4984. [More Information]

2015

  • Krishan, S., Richardson, D., Sahni, S. (2015). Adenosine Monophosphate-Activated Kinase and Its Key Role in Catabolism: Structure, Regulation, Biological Activity and Pharmacological Activation. Molecular Pharmacology, 87(3), 363-377. [More Information]
  • Bucur, O., Almasan, A., Zubarev, R., Friedman, M., Nicolson, G., Sumazin, P., Leabu, M., Nikolajczyk, B., Avram, D., Kunej, T., Richardson, D., Grau, G., et al (2015). An updated h-index measures both the primary and total scientific output of a researcher. Discoveries, 3(3), 1-6. [More Information]
  • Lane, D., Merlot, A., Huang, M., Bae, D., Jansson, P., Sahni, S., Kalinowski, D., Richardson, D. (2015). Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease. Biochimica et Biophysica Acta - General Subjects, 1853 (5), 1130-1144. [More Information]
  • Jansson, P., Yamagishi, T., Arvind, A., Seebacher, N., Gutierrez, E., Stacy, A., Maleki, S., Sharp, D., Sahni, S., Richardson, D. (2015). Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-Glycoprotein (Pgp). Journal of Biological Chemistry, 290(15), 9588-9603. [More Information]
  • Saleh Moussa, R., Kovacevic, Z., Richardson, D. (2015). Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types. Oncotarget, 6(30), 29694-29711. [More Information]
  • Seebacher, N., Richardson, D., Jansson, P. (2015). Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics. British Journal of Pharmacology, 172(10), 2557-2772. [More Information]
  • Stefani, C., Al-Eisawi, Z., Jansson, P., Kalinowski, D., Richardson, D. (2015). Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization. Journal of Inorganic Biochemistry, 152, 20-37. [More Information]
  • Potuckova, E., Roh, J., Machacek, M., Sahni, S., Stariat, J., Sestak, V., Jansova, H., Haskova, P., Jirkovska, A., Kalinowski, D., Richardson, D., et al (2015). In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PloS One, 10(10), 1-20. [More Information]
  • Krishan, S., Jansson, P., Gutierrez, E., Lane, D., Richardson, D., Sahni, S. (2015). Iron metabolism and autophagy: A poorly explored relationship that has important consequences for health and disease. Nagoya Journal of Medical Science, 77, 1-6.
  • Merlot, A., Kalinowski, D., Kovacevic, Z., Jansson, P., Lane, D., Sahni, S., Huang, M., Richardson, D. (2015). Making a case for albumin - a highly promising drug-delivery system. Future Medicinal Chemistry, 7(5), 553-556. [More Information]
  • Sestak, V., Stariat, J., Cermanova, J., Potuckova, E., Chladek, J., Roh, J., Bures, J., Jansova, H., Prusa, P., Sterba, M., Kalinowski, D., Richardson, D., et al (2015). Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 6(40), 42411-42428. [More Information]
  • Lui, G., Kovacevic, Z., Menezes, S., Kalinowski, D., Merlot, A., Sahni, S., Richardson, D. (2015). Novel Thiosemicarbazones Regulate the Signal Transducer and Activator of Transcription 3 (STAT3) Pathway: Inhibition of Constitutive and Interleukin 6-Induced Activation by Iron Depletion. Molecular Pharmacology, 87(3), 543-560. [More Information]
  • Merlot, A., Sahni, S., Lane, D., Fordham, A., Pantarat, N., Hibbs, D., Richardson, V., Doddareddy, M., Ong, J., Huang, M., Richardson, D., Kalinowski, D. (2015). Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells. Oncotarget, 6(12), 10374-10398. [More Information]
  • Jirkovska, A., Roh, J., Len�?ová-Popelová, O., Jirkovsky, E., Hrušková, K., Potuckova, E., Jansova, H., Haskova, P., Martinková, P., Eisner, T., Kalinowski, D., Richardson, D., et al (2015). Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicology Research, 4(4), 1098-1114. [More Information]
  • Lui, G., Kovacevic, Z., Richardson, V., Merlot, A., Kalinowski, D., Richardson, D. (2015). Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget, 6(22), 18748-18779. [More Information]
  • Wangpu, X., Yang, X., Zhao, J., Lu, J., Guan, S., Lu, J., Kovacevic, Z., Liu, W., Mi, L., Jin, R., Richardson, D., et al (2015). The metastasis suppressor, NDRG1, inhibits "stemness" of colorectal cancer via down-regulation of nuclear B-catenin and CD44. Oncotarget, 6(32), 33893-33911. [More Information]
  • Liu, W., Kovacevic, Z., Peng, Z., Jin, R., Wang, P., Yue, F., Zheng, M., Huang, M., Jansson, P., Richardson, V., Kalinowski, D., Lane, D., Merlot, A., Sahni, S., Richardson, D. (2015). The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: New therapeutic targets. Oncotarget, 6(34), 35522-35541. [More Information]
  • Liu, W., Yue, F., Zheng, M., Merlot, A., Bae, D., Huang, M., Lane, D., Jansson, P., Lui, G., Richardson, V., Sahni, S., Kalinowski, D., Kovacevic, Z., Richardson, D. (2015). The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget, 6(11), 8851-8874. [More Information]
  • Jansson, P., Kalinowski, D., Lane, D., Kovacevic, Z., Seebacher, N., Fouani, L., Sahni, S., Merlot, A., Richardson, D. (2015). The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacological Research, 100, 255-260. [More Information]
  • Sahni, S., Krishan, S., Palanimuthu, D., Richardson, D. (2015). The use of iron chelators in biocidal compositions: evaluation of patent, WO2014059417A1. Expert Opinion on Therapeutic Patents, 25(3), 367-372. [More Information]

2014

  • Krishan, S., Richardson, D., Sahni, S. (2014). AMP kinase (PRKAA1). Journal of Clinical Pathology, 67(9), 758-763. [More Information]
  • Lane, D., Richardson, D. (2014). Can we target the alpha2-macroglobulin-hepcidin interaction to treat pathologic hypoferremia? Future Medicinal Chemistry, 6(1), 13-16. [More Information]
  • Lane, D., Richardson, D. (2014). Chaperone turns gatekeeper: PCBP2 and DMT1 form an iron-transport pipeline. The Biochemical Journal, 462(1), e1-e3. [More Information]
  • Filak, L., Kalinowski, D., Bauer, T., Richardson, D., Arion, V. (2014). Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids. Inorganic Chemistry, 53(13), 6934-6943. [More Information]
  • Lane, D., Mills, T., Shafie, N., Merlot, A., Saleh Moussa, R., Kalinowski, D., Kovacevic, Z., Richardson, D. (2014). Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition. Biochimica et Biophysica Acta-Reviews on Cancer, 1845 (2), 166-181. [More Information]
  • Serda, M., Kalinowski, D., Rasko, N., Potuckova, E., Mrozek-Wilczkiewicz, A., Musiol, R., Małecki, J., Sajewicz, M., Ratuszna, A., Muchowicz, A., Richardson, D., et al (2014). Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships. PloS One, 9(10), 1-15. [More Information]
  • Anzovino, A., Lane, D., Huang, M., Richardson, D. (2014). Fixing frataxin: "ironing out" the metabolic defect in friedreich's ataxia. British Journal of Pharmacology, 171(8), 2174-2190. [More Information]
  • Sahni, S., Merlot, A., Krishnan, S., Jansson, P., Richardson, D. (2014). Gene of the month: BECN1. Journal of Clinical Pathology, 67(8), 656-660. [More Information]
  • Ataie-Kachoie, P., Pourgholami, M., Richardson, D., Morris, D. (2014). Gene of the month: Interleukin 6 (IL-6). Journal of Clinical Pathology, 67(11), 932-937. [More Information]
  • Lok, H., Sahni, S., Richardson, V., Kalinowski, D., Kovacevic, Z., Lane, D., Richardson, D. (2014). Glutathione S-Transferase and MRP1 Form an Integrated System Involved in the Storage and Transport of Dinitrosyl-Dithiolato Iron Complexes in Cells. Free Radical Biology and Medicine, 75, 14-29. [More Information]
  • Basha, M., Rodríguez, C., Richardson, D., Martínez, M., Bernhardt, P. (2014). Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia. Journal of Biological Inorganic Chemistry, 19(3), 349-357. [More Information]
  • Fang, B., Kovacevic, Z., Park, K., Kalinowski, D., Jansson, P., Lane, D., Sahni, S., Richardson, D. (2014). Molecular Functions of the Iron-Regulated Metastasis Suppressor, NDRG1, and its Potential as a Molecular Target for Cancer Therapy. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1845 (1), 1-19. [More Information]
  • Sahni, S., Krishan, S., Richardson, D. (2014). NDRG1 as a molecular target to inhibit the epithelial-mesenchymal transition: the case for developing inhibitors of metastasis. Future Medicinal Chemistry, 6(11), 1241-1244. [More Information]
  • Ellis, S., Kalinowski, D., Leotta, L., Huang, M., Jelfs, P., Sintchenko, V., Richardson, D., Triccas, J. (2014). Potent Anti-Mycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analogue, 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide. Molecular Pharmacology, 85(2), 269-278. [More Information]
  • Potuckova, E., Jansova, H., Machacek, M., Vavrova, A., Haskova, P., Tichotova, L., Richardson, V., Kalinowski, D., Richardson, D., Simunek, T. (2014). Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs. PloS One, 9(2), 1-15. [More Information]
  • Merlot, A., Richardson, D. (2014). Receptor Recognition and Lysosomal Targeting to Enhance Cytotoxicity of Novel Anti-Cancer Agents that Bind Iron and Copper. Vitamins & Trace Elements, 3(1), e125. [More Information]
  • Stariat, J., Suprunova, V., Roh, J., Sestak, V., Eisner, T., Filipsky, T., Mladenka, P., Nobilis, M., Simunek, T., Klimes, J., Kalinowski, D., Richardson, D., et al (2014). Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats. Biomedical Chromatography, 28(5), 621-629. [More Information]
  • Potuckova, E., Hrušková, K., Bures, J., Kovarikova, P., Spirkova, I., Pravdıkova, K., Kolbabova, L., Hergeselova, T., Haskova, P., Jansova, H., Richardson, V., Lane, D., Kalinowski, D., Richardson, D., et al (2014). Structure-Activity Relationships of Novel Salicylaldehyde Isonicotinoyl Hydrazone (SIH) Analogs: Iron Chelation, Anti-Oxidant and Cytotoxic Properties. PloS One, 9(11), 1-17. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2014). Synthesis and biological evaluation of 2-benzoylpyridine thiosemicarbazones in a dimeric system: Structure-activity relationship studies on their anti-proliferative and iron chelation efficacy. Journal of Inorganic Biochemistry, 141, 43-54. [More Information]
  • Lane, D., Richardson, D. (2014). The Active Role of Vitamin C in Mammalian Iron Metabolism: Much More Than Just Enhanced Iron Absorption!. Free Radical Biology and Medicine, 75, 69-83. [More Information]
  • Gutierrez, E., Richardson, D., Jansson, P. (2014). The Anti-Cancer Agent, Dp44mT, Overcomes Pro-Survival Autophagy by Two Mechanisms: Persistent Induction of Autophagosome Synthesis and Impairment of Lysosomal Integrity. Journal of Biological Chemistry, 289(48), 33568-33589. [More Information]
  • Lane, D., Merlot, A., Richardson, D. (2014). The lure of a LYR: The logistics of iron sulfur cluster delivery. Cell Metabolism, 19(3), 348-350. [More Information]
  • Sahni, S., Bae, D., Lane, D., Kovacevic, Z., Kalinowski, D., Jansson, P., Richardson, D. (2014). The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. Journal of Biological Chemistry, 289(14), 9692-9709. [More Information]
  • Merlot, A., Kalinowski, D., Richardson, D. (2014). Unraveling the mysteries of serum albumin-more than just a serum protein. Frontiers in Physiology, 5, 1-7. [More Information]

2013

  • Stefani, C., Jansson, P., Gutierrez, E., Bernhardt, P., Richardson, D., Kalinowski, D. (2013). Alkyl Substituted 2'-Benzoylpyridine Thiosemicarbazone Chelators with Potent and Selective Anti-Neoplastic Activity: Novel Ligands that Limit Methemoglobin Formation. Journal of Medicinal Chemistry, 56(1), 357-370. [More Information]
  • Walcourt, A., Kurantsin-Mills, J., Kwagyan, J., Adenuga, B., Kalinowski, D., Lovejoy, D., Lane, D., Richardson, D. (2013). Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: Effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool. Journal of Inorganic Biochemistry, 129, 43-51. [More Information]
  • Lane, D., Huang, M., Ting, S., Ramesh (Sivagurunathan), S., Richardson, D. (2013). Biochemistry of cardiomyopathy in the mitochondrial disease Friedreich's ataxia. The Biochemical Journal, 453(3), 321-336. [More Information]
  • Merlot, A., Pantarat, N., Menezes, S., Sahni, S., Richardson, D., Kalinowski, D. (2013). Cellular Uptake of the Antitumor Agent Dp44mT Occurs via a Carrier/Receptor-Mediated Mechanism. Molecular Pharmacology, 84(6), 911-924. [More Information]
  • Hua, S., Yao, M., Vignarajan, S., Witting, P., Hejazi, L., Gong, Z., Teng, Y., Niknami, M., Assinder, S., Richardson, D., Dong, Q. (2013). Cytosolic phospholipase A2alpha sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1831 (6), 1146-1157. [More Information]
  • Ford, S., Obeidy, P., Lovejoy, D., Bedford, M., Nichols, L., Chadwick, C., Tucker, O., Lui, G., Kalinowski, D., Jansson, P., Richardson, D., et al (2013). Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. British Journal of Pharmacology, 168(6), 1316-1328. [More Information]
  • Dixon, K., Lui, G., Kovacevic, Z., Zhang, D., Yao, M., Chen, Z., Dong, Q., Assinder, S., Richardson, D. (2013). Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer, 108(2), 409-419. [More Information]
  • Bambang, I., Lee, Y., Richardson, D., Zhang, D. (2013). Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal-epithelial transition in breast cancer cells. Oncogene, 32(10), 1240-1251. [More Information]
  • Huang, M., Austin, C., Sari, M., Suryo Rahmanto, Y., Ponka, P., Vyoral, D., Richardson, D. (2013). Hepcidin Bound to α2-Macroglobulin Reduces Ferroportin-1 Expression and Enhances Its Activity at Reducing Serum Iron Levels. Journal of Biological Chemistry, 288(35), 25450-25465. [More Information]
  • Lane, D., Huang, M., Richardson, D. (2013). Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression. The Biochemical Journal, 452(2), e3-e5. [More Information]
  • Stariat, J., Kovarikova, P., Kucera, R., Klimes, J., Kalinowski, D., Richardson, D., Ketola, R. (2013). Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry. Analytical and Bioanalytical Chemistry, 405(5), 1651-1661. [More Information]
  • Richardson, A., Kovacevic, Z., Richardson, D. (2013). Iron Chelation: Inhibition of Key Signaling Pathways in the Induction of the Epithelial Mesenchymal Transition in Pancreatic Cancer and Other Tumors. Critical Reviews in Oncogenesis, 18(5), 409-434. [More Information]
  • Sun, J., Zhang, D., Bae, D., Sahni, S., Jansson, P., Zheng, Y., Zhao, Q., Yue, F., Zheng, M., Kovacevic, Z., Richardson, D. (2013). Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis, 34(9), 1943-1954. [More Information]
  • Huang, M., Ramesh (Sivagurunathan), S., Ting, S., Jansson, P., Austin, C., Kelly, M., Semsarian, C., Zhang, D., Richardson, D. (2013). Molecular and Functional Alterations in a Mouse Cardiac Model of Friedreich Ataxia: Activation of the Integrated Stress Response, eIF2a Phosphorylation, and the Induction of Downstream Targets. American Journal of Pathology, 183(3), 745-757. [More Information]
  • Stacy, A., Jansson, P., Richardson, D. (2013). Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance. Molecular Pharmacology, 84(5), 655-669. [More Information]
  • Lane, D., Saletta, F., Suryo Rahmanto, Y., Kovacevic, Z., Richardson, D. (2013). N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion. PloS One, 8(2), 1-15. [More Information]
  • Merlot, A., Kalinowski, D., Richardson, D. (2013). Novel Chelators for Cancer Treatment: Where Are We Now? Antioxidants & Redox Signaling, 18(8), 973-1006. [More Information]
  • Yamagishi, T., Sahni, S., Sharp, D., Arvind, A., Jansson, P., Richardson, D. (2013). P-Glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration. Journal of Biological Chemistry, 288(44), 31761-31771. [More Information]
  • Ghalayini, M., Dong, Q., Richardson, D., Assinder, S. (2013). Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells. Bioscience Reports, 33(3), 451-464. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2013). Structure-activity studies of 4-phenyl-substituted 2'-benzoylpyridine thiosemicarbazones with potent and selective anti-tumour activity. Organic and Biomolecular Chemistry, 11(37), 6414-6425. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2013). Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: Novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy. Bioorganic & Medicinal Chemistry Letters, 23(4), 967-974. [More Information]
  • Sun, J., Zhang, D., Zheng, Y., Zhao, Q., Zheng, M., Kovacevic, Z., Richardson, D. (2013). Targeting the Metastasis Suppressor, NDRG1, Using Novel Iron Chelators: Regulation of Stress Fiber-Mediated Tumor Cell Migration via Modulation of the ROCK1/pMLC2 Signaling Pathway. Molecular Pharmacology, 83(2), 454-469. [More Information]
  • Lui, G., Obeidy, P., Ford, S., Tselepis, C., Sharp, D., Jansson, P., Kalinowski, D., Kovacevic, Z., Lovejoy, D., Richardson, D. (2013). The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology, 83(1), 179-190. [More Information]
  • Kovacevic, Z., Chikhani, S., Lui, G., Ramesh (Sivagurunathan), S., Richardson, D. (2013). The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways. Antioxidants & Redox Signaling, 18(8), 874-887. [More Information]
  • Kalinowski, D., Jansson, P., Kovacevic, Z., Richardson, D. (2013). The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. Redox Report, 18(2), 48-50. [More Information]
  • Bae, D., Jansson, P., Huang, M., Kovacevic, Z., Kalinowski, D., Lee, C., Sahni, S., Richardson, D. (2013). The role of NDRG1 in the pathology and potential treatment of human cancers. Journal of Clinical Pathology, 66(11), 911-917. [More Information]
  • Lane, D., Chikhani, S., Richardson, V., Richardson, D. (2013). Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1833 (6), 1527-1541. [More Information]

2012

  • Yu, Y., Suryo Rahmanto, Y., Richardson, D. (2012). Bp44mT: An Orally-Active Iron Chelator of the Thiosemicarbazone Class with Potent Anti-Tumour Efficacy. British Journal of Pharmacology, 165(1), 148-166. [More Information]
  • Debebe, Z., Nekhai, S., Ashenafi, M., Lovejoy, D., Kalinowski, D., Gordeuk, V., Byrnes, W., Richardson, D., Karla, P. (2012). Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 906, 25-32. [More Information]
  • Gao, D., Bambang, I., Putti, T., Lee, Y., Richardson, D., Zhang, D. (2012). ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58(IPK). Laboratory Investigation, 92(2), 200-213. [More Information]
  • Basha, M., Chartres, J., Pantarat, N., Akbar Ali, M., Mirza, A., Kalinowski, D., Richardson, D., Bernhardt, P. (2012). Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity. Dalton Transactions, 41(21), 6536-6548. [More Information]
  • Whitnall, M., Suryo Rahmanto, Y., Huang, M., Saletta, F., Lok, H., Gutierrez, L., Lazaro, F., Fleming, A., ST Pierre, T., Mikhael, M., Richardson, D., et al (2012). Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proceedings of the National Academy of Sciences of the United States of America, 109(50), 20590-20595. [More Information]
  • Brychtova, K., Dvorakova, L., Opatrilova, R., Raich, I., Kacerova, S., Placek, L., Kalinowski, D., Richardson, D., Jampilek, J. (2012). Investigation of substituted 6-aminohexanoates as skin penetration enhancers. Bioorganic and Medicinal Chemistry, 20(1), 86-95. [More Information]
  • Yu, Y., Gutierrez, E., Kovacevic, Z., Saletta, F., Obeidy, P., Suryo Rahmanto, Y., Richardson, D. (2012). Iron chelators for the treatment of cancer. Current Medicinal Chemistry, 19(17), 2689-2702. [More Information]
  • Stariat, J., Sestak, V., Vavrova, K., Nobilis, M., Kollarova, Z., Klimes, J., Kalinowski, D., Richardson, D., Kovarikova, P. (2012). LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT. Analytical and Bioanalytical Chemistry, 403(1), 309-321. [More Information]
  • Suryo Rahmanto, Y., Bal, S., Loh, K., Yu, Y., Richardson, D. (2012). Melanotransferrin: Search for a function. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1820 (3), 237-243. [More Information]
  • Quach, P., Gutierrez, E., Basha, M., Kalinowski, D., Sharpe, P., Lovejoy, D., Bernhardt, P., Jansson, P., Richardson, D. (2012). Methemoglobin Formation by Triapine, Di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone (Dp44mT), and Other Anticancer Thiosemicarbazones: Identification of Novel Thiosemicarbazones and Therapeutics That Prevent This Effect. Molecular Pharmacology, 82(1), 105-114. [More Information]
  • Lok, H., Suryo Rahmanto, Y., Hawkins, C., Kalinowski, D., Morrow, C., Townsend, A., Ponka, P., Richardson, D. (2012). Nitric oxide storage and transport in cells are mediated by glutathione S-transferase P1-1 and Multidrug Resistant Protein 1 via Dinitrosyl iron complexes. Journal of Biological Chemistry, 287(1), 607-618. [More Information]
  • Suryo Rahmanto, Y., Kalinowski, D., Lane, D., Lok, H., Richardson, V., Richardson, D. (2012). Nitrogen Monoxide (NO) Storage and Transport by Dinitrosyl-Dithiol-Iron Complexes: Long-Lived NO that is Trafficked by Interacting Proteins. Journal of Biological Chemistry, 287(10), 6960-6968. [More Information]
  • Lovejoy, D., Sharp, D., Seebacher, N., Obeidy, P., Prichard, T., Stefani, C., Basha, M., Sharpe, P., Jansson, P., Kalinowski, D., Richardson, D., et al (2012). Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo. Journal of Medicinal Chemistry, 55(16), 7230-7244. [More Information]
  • Correnti, C., Richardson, V., Sia, A., Bandaranayake, A., Ruiz, M., Suryo Rahmanto, Y., Kovacevic, Z., Clifton, M., Holmes, M., Kaiser, B., Richardson, D., et al (2012). Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines. PloS One, 7(8), 1-15. [More Information]
  • Li, C., Lonn, M., Xu, X., Maghzal, G., Frazer, D., Thomas, S., Halliwell, B., Richardson, D., Anderson, G., Stocker, R. (2012). Sustained expression of heme oxygenase-1 alters iron homeostasis in nonerythroid cells. Free Radical Biology and Medicine, 53(2), 366-374. [More Information]
  • Serda, M., Kalinowski, D., Mrozek-Wilczkiewicz, A., Musiol, R., Szurko, A., Ratuszna, A., Pantarat, N., Kovacevic, Z., Merlot, A., Richardson, D., et al (2012). Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorganic & Medicinal Chemistry Letters, 22(17), 5527-5531. [More Information]
  • Kovacevic, Z., Richardson, D. (2012). Targeting Iron in Cancer Cells: A New Strategy to Inhibit Metastatic Progression. Vitamins & Trace Elements, 1(3), 1-2. [More Information]
  • Chen, Z., Zhang, D., Yue, F., Zheng, M., Kovacevic, Z., Richardson, D. (2012). The iron chelators Dp44mT and DFO inhibit TGF-B-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). Journal of Biological Chemistry, 287(21), 17016-17028. [More Information]

2011

  • Lovejoy, D., Jansson, P., Brunk, U., Wong, J., Ponka, P., Richardson, D. (2011). Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes. Cancer Research, 71(17), 5871-5880. [More Information]
  • Saletta, F., Suryo Rahmanto, Y., Siafakas, A., Richardson, D. (2011). Cellular Iron Depletion and the Mechanisms involved in the Iron-dependent Regulation of the Growth Arrest and DNA Damage Family of Genes. Journal of Biological Chemistry, 286(41), 35396-35406. [More Information]
  • Yu, Y., Richardson, D. (2011). Cellular Iron Depletion Stimulates the JNK and p38 MAPK Signaling Transduction Pathways, Dissociation of ASK1-Thioredoxin, and Activation of ASK1. Journal of Biological Chemistry, 286(17), 15413-15427. [More Information]
  • Kovacevic, Z., Yu, Y., Richardson, D. (2011). Chelators to the rescue: different horses for different courses!. Chemical Research in Toxicology, 24(3), 279-282. [More Information]
  • Zhang, D., Richardson, D. (2011). Endoplasmic reticulum protein 29 (ERp29): An emerging role in cancer. The International Journal of Biochemistry and Cell Biology, 43(1), 33-36. [More Information]
  • Stefani, C., Punnia-Moorthy, G., Lovejoy, D., Jansson, P., Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2011). Halogenated 2'-Benzoylpyridine Thiosemicarbazone (XBpT) Chelators with Potent and Selective Anti-Neoplastic Activity: Relationship to Intracellular Redox Activity. Journal of Medicinal Chemistry, 54(19), 6936-6948. [More Information]
  • Saletta, F., Kovacevic, Z., Richardson, D. (2011). Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules. Future Medicinal Chemistry, 3(16), 1983-1986. [More Information]
  • Debebe, Z., Ammosova, T., Breuer, D., Lovejoy, D., Kalinowski, D., Karla, P., Kumar, K., Jarebtsova, M., Ray, P., Kashanchi, F., Richardson, D., et al (2011). Iron Chelators of the Di-2-pyridylketone Thiosemicarbazone and 2-Benzoylpyridine Thiosemicarbazone Series Inhibit HIV-1 Transcription: Identification of Novel Cellular Targets-Iron, Cyclin-Dependent Kinase (CDK) 2, and CDK9. Molecular Pharmacology, 79(1), 185-196. [More Information]
  • Bernhardt, P., Richardson, D. (2011). Metal chelation. Current Topics in Medicinal Chemistry, 11(5), 482-482. [More Information]
  • Huang, M., Lane, D., Richardson, D. (2011). Mitochondrial Mayhem: The Mitochondrion as a Modulator of Iron Metabolism and Its Role in Disease. Antioxidants & Redox Signaling, 15(12), 3003-3019. [More Information]
  • Kovacevic, Z., Chikhani, S., Lovejoy, D., Richardson, D. (2011). Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A new Strategy for the Treatment of Pancreatic Cancer. Molecular Pharmacology, 80(4), 598-609. [More Information]
  • Sharpe, P., Richardson, D., Kalinowski, D., Bernhardt, P. (2011). Synthetic and natural products as iron chelators. Current Topics in Medicinal Chemistry, 11(5), 591-607. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Yu, Y., Suryo Rahmanto, Y., Sharpe, P., Bernhardt, P., Richardson, D. (2011). The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Current Topics in Medicinal Chemistry, 11(5), 483-499. [More Information]
  • Kovacevic, Z., Ramesh (Sivagurunathan), S., Mangs, A., Chikhani, S., Zhang, D., Richardson, D. (2011). The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis, 32(5), 732-740. [More Information]
  • Yu, Y., Suryo Rahmanto, Y., Hawkins, C., Richardson, D. (2011). The Potent and Novel Thiosemicarbazone Chelators Di-2- pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2- Benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity. Molecular Pharmacology, 79(6), 921-931. [More Information]

2010

  • Miao, Q., Xu, D., Wang, Z., Xu, L., Wang, T., Wu, Y., Lovejoy, D., Kalinowski, D., Richardson, D., Nie, G., et al (2010). Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents. Biomaterials, 31(28), 7364-7375. [More Information]
  • Bendova, P., Mackova, E., Haskova, P., Vavrova, A., Jirkovsky, E., Sterba, M., Popelova, O., Kalinowski, D., Kovarikova, P., Vavrova, K., Richardson, D., et al (2010). Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 23(6), 1105-1114. [More Information]
  • Liu, J., Obando Gutierrez, D., Schipanski, L., Groebler, L., Witting, P., Kalinowski, D., Richardson, D., Codd, R. (2010). Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron Overload. Journal of Medicinal Chemistry, 53(3), 1370-1382. [More Information]
  • Stariat, J., Kovarikova, P., Klimes, J., Kalinowski, D., Richardson, D. (2010). Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT. Analytical and Bioanalytical Chemistry, 397(1), 161-171. [More Information]
  • Lane, D., Richardson, D. (2010). Frataxin, a molecule of mystery: trading stability for function in its iron-binding site. Biochemical Journal, 426(2), e1-e3. [More Information]
  • Brychtova, K., Opatrilova, R., Raich, I., Kalinowski, D., Dvorakova, L., Placek, L., Csollei, J., Richardson, D., Jampilek, J. (2010). Investigating the activity of 2-substituted alkyl-6-(25-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers. Bioorganic and Medicinal Chemistry, 18(24), 8556-8565. [More Information]
  • Mrozek-Wilczkiewicz, A., Kalinowski, D., Musiol, R., Finster, J., Szurko, A., Serafin, K., Knas, M., Kamalapuram, S., Kovacevic, Z., Jampilek, J., Richardson, D., et al (2010). Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones. Bioorganic and Medicinal Chemistry, 18(7), 2664-2671. [More Information]
  • Otevrel, J., Mandelova, Z., Pesko, M., Guo, J., Kralova, K., Sersen, F., Vejsova, M., Kalinowski, D., Kovacevic, Z., Coffey, A., Richardson, D., et al (2010). Investigating the Spectrum of Biological Activity of Ring-Substituted Salicylanilides and Carbamoylphenylcarbamates. Molecules, 15(11), 8122-8142. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Quach, P., Burn (Wong), J., Richardson, D. (2010). Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Current Drug Delivery, 7(3), 194-207. [More Information]
  • Merlot, A., Pantarat, N., Lovejoy, D., Kalinowski, D., Richardson, D. (2010). Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer. Molecular Pharmacology, 78(4), 675-684. [More Information]
  • Richardson, D., Lane, D., Becker, E., Huang, M., Suryo Rahmanto, Y., Sheftel, A., Ponka, P. (2010). Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proceedings of the National Academy of Sciences of the United States of America, 107(24), 10775-10782. [More Information]
  • Jansson, P., Sharpe, P., Bernhardt, P., Richardson, D. (2010). Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity. Journal of Medicinal Chemistry, 53(15), 5759-5769. [More Information]
  • Singleton, W., McInnes, K., Cater, M., Winnall, W., McKirdy, R., Yu, Y., Taylor, P., Ke, B., Richardson, D., Mercer, J., et al (2010). Role of Glutaredoxin1 and Glutathione in Regulating the Activity of the Copper-transporting P-type ATPases, ATP7A and ATP7B. Journal of Biological Chemistry, 285, 27111-27121. [More Information]
  • Richardson, D., Huang, M., Whitnall, M., Becker, E., Ponka, P., Suryo Rahmanto, Y. (2010). The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. Journal of Molecular Medicine, 88(4), 323-329. [More Information]
  • Jansson, P., Hawkins, C., Lovejoy, D., Richardson, D. (2010). The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study. Journal of Inorganic Biochemistry, 104(11), 1224-1228. [More Information]
  • Saletta, F., Suryo Rahmanto, Y., Richardson, D. (2010). The Translational Regulator eIF3a: The Tricky eIF3 Subunit!. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1806 (2), 275-86. [More Information]

2009

  • Richardson, D., Kalinowski, D., Richardson, V., Sharpe, P., Lovejoy, D., Islam, M., Bernhardt, P. (2009). 2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity. Journal of Medicinal Chemistry, 52(5), 1459-1470. [More Information]
  • Noulsri, E., Richardson, D., Lerdwana, S., Fucharoen, S., Yamagishi, T., Kalinowski, D., Pattanapanyasat, K. (2009). Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. American Journal Of Hematology, 84(3), 170-176. [More Information]
  • Bohlken, A., Cheung, B., Bell, J., Koach, J., Smith, S., Sekyere, E., Thomas, W., Norris, M., Lovejoy, D., Richardson, D. (2009). ATP7A is a novel target of retinoic acid receptor β2 in neuroblastoma cells. British Journal of Cancer, 100(1), 96-105. [More Information]
  • Richardson, D., Kalinowski, D., Lau, S., Jansson, P., Lovejoy, D. (2009). Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochimica et Biophysica Acta, 1790 (7), 702-717. [More Information]
  • Richardson, D. (2009). Chelators as Anti-Cancer Drugs. In Manfred Schwab (Eds.), Encyclopedia of Cancer, Vol. 1, (pp. 598-601). Germany: Springer.
  • Huang, M., Becker, E., Whitnall, M., Suryo Rahmanto, Y., Ponka, P., Richardson, D. (2009). Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proceedings of the National Academy of Sciences of the United States of America, 106(38), 16381-16386. [More Information]
  • Suryo Rahmanto, Y., Richardson, D. (2009). Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype. Biochimica et Biophysica Acta, 1793 (7), 1210-1217. [More Information]
  • Siafakas, A., Richardson, D. (2009). Growth arrest and DNA damage-45 alpha (GADD45alpha). The International Journal of Biochemistry and Cell Biology, 41(5), 986-989. [More Information]
  • Peslova, G., Petrak, J., Kuzelova, K., Hrdy, I., Halada, P., Kuchel, P., Soe-Lin, S., Ponka, P., Sutak, R., Becker, E., Huang, M., Suryo Rahmanto, Y., Richardson, D., Vyoral, D. (2009). Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood, 113(24), 6225-6236. [More Information]
  • Stariat, J., Kovarikova, P., Klimes, J., Lovejoy, D., Kalinowski, D., Richardson, D. (2009). HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 877(3), 316-322. [More Information]
  • Saletta, F., Suryo Rahmanto, Y., Noulsri, E., Richardson, D. (2009). Iron Chelator-Mediated Alterations in Gene Expression: Identification of Novel Iron-Regulated Molecules that are Molecular Targets of HIF-1{alpha} and p53. Molecular Pharmacology, 77(3), 443-458. [More Information]
  • Bernhardt, P., Sharpe, P., Islam, M., Lovejoy, D., Kalinowski, D., Richardson, D. (2009). Iron Chelators of the Dipyridylketone Thiosemicarbazone Class: Precomplexation and Transmetalation Effects on Anticancer Activity. Journal of Medicinal Chemistry, 52(2), 407-415. [More Information]
  • Sheftel, A., Richardson, D., Prchal, J., Ponka, P. (2009). Mitochondrial Iron Metabolism and Sideroblastic Anemia. Acta Haematologica, 122(2-3), 120-133. [More Information]
  • Assinder, S., Dong, Q., Mangs, A., Richardson, D. (2009). Pharmacological targeting of the integrated protein kinase B, phosphatase and tensin homolog deleted on chromosome 10, and transforming growth Factor-β pathways in prostate cancer. Molecular Pharmacology, 75(3), 429-436. [More Information]
  • Mladenka, P., Kalinowski, D., Haskova, P., Bobrovova, Z., Hrdina, R., Simunek, T., Nachtigal, P., Semecky, V., Vavrova, J., Holeckova, M., Jansson, P., Richardson, D., et al (2009). The Novel Iron Chelator, 2-Pyridylcarboxaldehyde 2-Thiophenecarboxyl Hydrazone, Reduces Catecholamine-Mediated Myocardial Toxicity. Chemical Research in Toxicology, 22(1), 208-217. [More Information]
  • Assinder, S., Dong, Q., Kovacevic, Z., Richardson, D. (2009). The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal, 417(2), 411-421. [More Information]
  • Yu, Y., Kalinowski, D., Kovacevic, Z., Siafakas, A., Jansson, P., Stefani, C., Lovejoy, D., Sharpe, P., Bernhardt, P., Richardson, D. (2009). Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. Journal of Medicinal Chemistry, 52(17), 5271-5294. [More Information]
  • Kalinowski, D., Quach, P., Richardson, D. (2009). Thiosemicarbazones: the new wave in cancer treatment. Future Medicinal Chemistry, 1(6), 1143-1151. [More Information]

2008

  • Long, S., Jirku, M., Mach, J., Ginger, M., Sutak, R., Richardson, D., Tachezy, J., Lukes, J. (2008). Ancestral roles of eukaryotic frataxin: mitochondrial frataxin function and heterologous expression of hydrogenosomal Trichomonas homologues in trypanosomes. Molecular Microbiology, 69(1), 94-109. [More Information]
  • Farnaud, S., Amini, M., Rapisarda, C., Cammack, R., Bui, T., Drake, A., Evans, R., Suryo Rahmanto, Y., Richardson, D. (2008). Biochemical and spectroscopic studies of human melanotransferrin (MTf): Electron-paramagnetic resonance evidence for a difference between the iron-binding site of MTf and other transferrins. The International Journal of Biochemistry and Cell Biology, 40(12), 2739-2745. [More Information]
  • Kalinowski, D., Richardson, D. (2008). Cellular and Molecular Biology of Iron-Binding Proteins. In Rudolfs K. Zalups, D. James Koropatnick (Eds.), Cellular and Molecular Biology of Metals.
  • Lovejoy, D., Yu, Y., Richardson, D. (2008). Chelators as Anti-Cancer Drugs. In Manfred Schwab (Eds.), Encyclopedia of Cancer, Vol. 1. Germany: Springer.
  • Sutak, R., Lesuisse, E., Tachezy, J., Richardson, D. (2008). Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends in Microbiology, 16(6), 261-8. [More Information]
  • Opletalova, V., Kalinowski, D., Vesjova, M., Kunes, J., Pour, M., Jampılek, J., Buchta, V., Richardson, D. (2008). Identification and Characterization of Thiosemicarbazones with Antifungal and Antitumor Effects: Cellular Iron Chelation Mediating Cytotoxic Activity. Chemical Research in Toxicology, 21(9), 1878-1889. [More Information]
  • Xu, X., Sutak, R., Richardson, D. (2008). Iron Chelation by Clinically Relevant Anthracyclines: Alteration in Expression of Iron-Regulated Genes and Atypical Changes in Intracellular Iron Distribution and Trafficking. Molecular Pharmacology, 73(3), 833-844. [More Information]
  • Lim, C., Kalinowski, D., Richardson, D. (2008). Protection Against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich's Ataxia Fibroblasts using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class. Molecular Pharmacology, 74(1), 225-235. [More Information]
  • Sutak, R., Xu, X., Whitnall, M., Kashem, M., Vyoral, D., Richardson, D. (2008). Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism. Proteomics, 8, 1731-1741. [More Information]
  • Lim, S., Raftery, M., Cai, H., Hsu, K., Yan, W., Hseih, H., Watts, R., Richardson, D., Thomas, S., Perry, M., et al (2008). S-nitrosylated S100A8: novel anti-inflammatory properties. Journal of Immunology, 181(8), 5627-5636. [More Information]
  • Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2008). Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. Journal of Medicinal Chemistry, 51(2), 331-344. [More Information]
  • Suryo Rahmanto, Y., Sekyere, E., Dunn, L., Richardson, D. (2008). The function of the membrane-bound transferrin homolog, melanotransferrin (melanoma tumour antigen p97). In H. Fuchs (Eds.), Iron Metabolism and Disease, (pp. 219-239). Kerala, India: Research Signpost.
  • Kovacevic, Z., Fu, D., Richardson, D. (2008). The iron-regulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets. Biochimica et Biophysica Acta, 1783 (10), 1981-1992. [More Information]
  • Whitnall, M., Suryo Rahmanto, Y., Sutak, R., Xu, X., Becker, E., Mikhael, M., Ponka, P., Richardson, D. (2008). The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proceedings of the National Academy of Sciences of the United States of America, 105(28), 9757-9762. [More Information]
  • Richardson, D., Lok, H. (2008). The nitric oxide-iron interplay in mammalian cells: transport and storage of dinitrosyl iron complexes. Biochimica et Biophysica Acta, 1780 (4), 638-651. [More Information]
  • Suryo Rahmanto, Y., Richardson, D. (2008). The Physiological and Pathophysiological Roles of Melanotransferrin: Role of Melanotransferrin in Cell Proliferation, Migration and Melanoma Tumourigenesis. Saarbrucken, Germany: VDM Verlag Dr Muller.
  • Bernhardt, P., Wilson, G., Sharpe, P., Kalinowski, D., Richardson, D. (2008). Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. Journal of Biological Inorganic Chemistry, 13(1), 107-119. [More Information]

2007

  • Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2007). Design, Synthesis, and Characterization of New Iron Chelators with Anti-Proliferative Activity: Structure-Activity Relationships of Novel Thiohydrazone Analogues. Journal of Medicinal Chemistry, 50(24), 6212-6225. [More Information]
  • Kalinowski, D., Yu, Y., Sharpe, P., Islam, M., Liao, Y., Lovejoy, D., Kumar, N., Bernhardt, P., Richardson, D. (2007). Design, Synthesis, and Characterization of Novel Iron Chelators: Structure-Activity Relationships of the 2-Benzoylpyridine Thiosemicarbazone Series and Their 3-Nitrobenzoyl Analogues as Potent Antitumor Agents. Journal of Medicinal Chemistry, 50(15), 3716-3729. [More Information]
  • Mrkvicková, Z., Kovaríková, P., Klimes, J., Kalinowski, D., Richardson, D. (2007). Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity. Journal of Pharmaceutical and Biomedical Analysis, 43(4), 1343-1351. [More Information]
  • Richardson, D., Suryo Rahmanto, Y. (2007). Differential regulation of the Menkes and Wilson disease copper transporters by hormones: an integrated model of metal transport in the placenta. Biochemical Journal, 402(2), e1-e3. [More Information]
  • Kalinowski, D., Richardson, D. (2007). Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chemical Research in Toxicology, 20(5), 715-720. [More Information]
  • Bernhardt, P., Chin, P., Sharpe, P., Richardson, D. (2007). Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity. Dalton Transactions, 30, 3232-3244. [More Information]
  • Suryo Rahmanto, Y., Dunn, L., Richardson, D. (2007). Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo. Carcinogenesis, 28(10), 2172-2183. [More Information]
  • Musiol, R., Jampilek, J., Kralova, K., Richardson, D., Kalinowski, D., Podeszwa, B., Finster, J., Niedbala, H., Palka, A., Polanski, J. (2007). Investigating biological activity spectrum for novel quinoline analogues. Bioorganic and Medicinal Chemistry, 15(3), 1280-1288. [More Information]
  • Podeszwa, B., Niedbala, H., Polanski, J., Musiol, R., Tabak, D., Finster, J., Serafin, K., Milczarek, M., Wietrzyk, J., Boryczka, S., Kalinowski, D., Richardson, D., et al (2007). Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. Bioorganic and Medicinal Chemistry Letters, 17(22), 6138-6141. [More Information]
  • Podeszwa, B., Niedbala, H., Polanski, J., Musiol, R., Tabak, D., Finster, J., Serafin, K., Milczarek, M., Wietrzyk, J., Boryczka, S., Kalinowski, D., Richardson, D., et al (2007). Investigating the antiproliferative and styrylquinolinecarboxyli activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. Bioorganic and Medicinal Chemistry Letters, 17(22), 6138-6141. [More Information]
  • Fu, D., Richardson, D. (2007). Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood, 110(2), 752-761. [More Information]
  • Nurtjahja-Tjendraputra, E., Fu, D., Phang, J., Richardson, D. (2007). Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood, 109(9), 4045-4054.
  • Debebe, Z., Ammosova, T., Jerebtsova, M., Kurantsin-Mills, J., Niu, X., Charles, S., Richardson, D., Ray, P., Gordeuk, V., Nekhai, S. (2007). Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology, 367(2), 324-333. [More Information]
  • Suryo Rahmanto, Y., Dunn, L., Richardson, D. (2007). The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark - from iron metabolism to tumorigenesis. Oncogene, 26(42), 6113-6124. [More Information]
  • Yu, Y., Kovacevic, Z., Richardson, D. (2007). Tuning Cell Cycle Regulation With an Iron Key. Cell Cycle, 6(16), 1982-1994. [More Information]

2006

  • Whitnall, M., Howard, J., Ponka, P., Richardson, D. (2006). A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proceedings of the National Academy of Sciences of the United States of America, 103(40), 14901-14906. [More Information]
  • Nurtjahja-Tjendraputra, E., Fu, D., Phang, J., Richardson, D. (2006). Cellular Iron Levels Regulate Cyclin D1 Expression via the Proteasome: a Link to Iron-Depletion Mediated Grwoth Suppression. The Young Investigators Symposium.
  • Yu, Y., Wong, J., Lovejoy, D., Kalinowski, D., Richardson, D. (2006). Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clinical Cancer Research, 12(23), 6876-6883. [More Information]
  • Richardson, D., Sharpe, P., Lovejoy, D., Senaratne, D., Kalinowski, D., Islam, M., Bernhardt, P. (2006). Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity. Journal of Medicinal Chemistry, 49(22), 6510-6521. [More Information]
  • Suryo Rahmanto, Y., Richardson, D., Dunne, L., Sekyere, E. (2006). Identification of melanotransferin (p97) associated genes using in vitro and in vivo models. Free Radical Research, 40, S55.
  • Nurtjahja-Tjendraputra, E., Fu, D., Phang, J., Richardson, D. (2006). Iron Chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood, 109(9), 4045-4054. [More Information]
  • Richardson, D., Lovejoy, D. (2006). Iron mining" if to inhibit tumor growth.". Blood, 108(7), 2140-2140.
  • Dunn, L., Suryo Rahmanto, Y., Richardson, D. (2006). Iron uptake and metabolism in the new millennium. Trends in Cell Biology, 17(2), 93-100. [More Information]
  • Whitnall, M., Richardson, D. (2006). Iron: a new target for pharmacological intervention in neurodegenerative diseases. Seminars in Pediatric Neurology, 13(3), 186-97. [More Information]
  • Watts, R., Hawkins, C., Ponka, P., Richardson, D. (2006). Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proceedings of the National Academy of Sciences of the United States of America, 103(20), 7670-7675. [More Information]
  • Lovejoy, D., Kalinowski, D., Bernhardt, P., Richardson, D. (2006). PCTH: A Novel Orally Active Chelator for the Treatment of Iron Overload Disease. Hemoglobin, 30(1), 93-104. [More Information]
  • Davies, N., Suryo Rahmanto, Y., Chitambar, C., Richardson, D. (2006). Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates. Journal of Pharmacology and Experimental Therapeutics, 317(1), 153-162. [More Information]
  • Owusu Sekyere, E., Dunn, L., Suryo Rahmanto, Y., Richardson, D. (2006). Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood, 107(7), 2599-2601. [More Information]
  • Sekyere, E., Dunn, L., Suryo Rahmanto, Y., Richardson, D. (2006). Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood, 107(6), 2599-2601. [More Information]
  • Dunn, L., Owusu Sekyere, E., Suryo Rahmanto, Y., Richardson, D. (2006). The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis, 27(11), 2157-2169. [More Information]
  • Dunn, L., Sekyere, E., Rahmanto, Y., Richardson, D. (2006). The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis, 27(11), 2157-2169. [More Information]
  • Kovacevic, Z., Richardson, D. (2006). The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 27(12), 2355-2366. [More Information]

2005

  • Napier, I., Ponka, P., Richardson, D. (2005). Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood, 105(5), 1867-74. [More Information]
  • Fu, D., Richardson, D. (2005). Iron-dependent regulation of the cell cycle: the expression of the universal cyclin-dependent kinase inhibitor p21(cipl/wafl) after iron chelation. BioIron 2005, Prague.
  • Fu, D., Richardson, D. (2005). The cyclin-dependent kinast inhibitor p21CIPI/WAF1 is degraded by the proteasomal pathway after iron chelation. Seventh Annual MEPSA Scientific Conference.
  • Kalinowski, D., Richardson, D. (2005). The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharmacological Reviews, 57(4), 547-583. [More Information]

2003

  • Little, C., Cramp, J., Curtis, C., Richardson, D., Schoenherr, B., Innes, J., Jones, S., Caterson, B. (2003). Canine articular catilage degradation: The role of catabolic cytokines. 49th Annual Meeting of the Orthopaedic Research Society, United states: Orthopaedic Research Society.
  • Bernhardt, P., Caldwell, L., Lovejoy, D., Richardson, D. (2003). Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta Crystallographica. Section C: Crystal Structure Communications, 59(11), o629-o633. [More Information]
  • Becker, E., Lovejoy, D., Greer, J., Watts, R., Richardson, D. (2003). Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. British Journal of Pharmacology, 138(5), 819-830. [More Information]

2001

  • Thomas, S., Salahifar, H., Mashima, R., Hunt, N., Richardson, D., Stocker, R. (2001). Antioxidants Inhibit Indoleamine 2,3-Dioxygenase in IFN-gamma-Activated Human Macrophages: Posttranslational Regulation by Pyrrolidine Dithiocarbamate. Journal of Immunology, 166, 6332-6340.

To update your profile click here. For support on your academic profile contact .